Novartis Research and Development  
KJX839/Inclisiran 
Clinical Trial Protocol CKJX839D12304 / [STUDY_ID_REMOVED]
A Doubl
e-blind, Randomized, Placebo - and Active -
Comparator Controlled Study to Evaluate the Efficacy of 
Inclisiran as Monotherapy in Patients with Primary 
Hypercholesterolemia Not Receiving Lipid-Lowering 
Therapy (VictORION -Mono) 
Document type:  Amended Protocol  Version  (Clean ) 
EUDRACT number:  2022 -001109 -29 
Version number:  V01 (Amended Protocol ) 
Clinical Trial Phase:  III 
Release date:  08-Feb-2023 (content final)
Property of Novartis  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of Novartis  
Clinical Trial Protocol Template Version 4.0 dated 15 -Feb- 2021  
Novartis  Confidential  Page 2 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Table of contents  
Table of contents ................................................................................................................. 2 
List of tables  ........................................................................................................................ 5 
List of figures  ...................................................................................................................... 6 
List of abbreviations  ............................................................................................................ 7 
Glossary of terms  ............................................................................................................... 10 
Amendment 1 (08- Feb-2023) ............................................................................................ 13 
Protocol summary  .............................................................................................................. 17 
1 Introduction ....................................................................................................................... 20 
1.1 Background ............................................................................................................ 20 
1.2 Purpose .................................................................................................................. 21 
2 Objectives, endpoints and estimands  ................................................................................. 22 
2.1 Primary estimands  ................................................................................................. 22 
2.2 Secondary estimands ............................................................................................. 23 
3 Study design ...................................................................................................................... 24 
3.1 Off-site procedures  ................................................................................................ 24 
3.1.1  Responsibility of Investigators .............................................................. 25 
3.1.2  Responsibility of OHPs ......................................................................... 25 
3.1.3  Telemedicine  ......................................................................................... 25 
3.2 Screening  ............................................................................................................... 26 
3.3 Double- blind treatment  .......................................................................................... 26 
3.4 Safety Follow -up/EOS ........................................................................................... 27 
4 Rationale ............................................................................................................................ 27 
4.1 Rationale for study design ..................................................................................... 27 
4.1.1  Rationale for choice of background therapy ......................................... 27 
4.2 Rationale for dose/regimen and duration of treatment  .......................................... 28 
4.3 Rationale for choice of control drugs (comparator/placebo)  ................................. 28 
4.4 Purpose and timing of interim analyses/design adaptations .................................. 28 
4.5 Risks and benefits .................................................................................................. 29 
4.6 Rationale for planned off- site procedures  .............................................................. 30 
4.7 Rationale for Public Health Emergency mitigation procedures ............................ 30 
5 Study Population ............................................................................................................... 30 
5.1 Inclusion criteria  .................................................................................................... 30 
5.2 Exclusion criteria  ................................................................................................... 31 
6 Treatment  ........................................................................................................................... 33 
6.1 Study treatment ...................................................................................................... 33 
Novartis  Confidential  Page 3 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
6.1.1  Investigational and control drugs .......................................................... 33 
6.1.2  Additional study treatments .................................................................. 33 
6.1.3  Treatment arms/group  ........................................................................... 33 
6.1.4  Treatment duration  ................................................................................ 34 
6.2 Other treatment(s)  .................................................................................................. 34 
6.2.1  Concomitant therapy  ............................................................................. 34 
6.2.2  Prohibited medication  ........................................................................... 35 
6.3 Preparation and dispensation  ................................................................................. 36 
6.3.1  Handling of study treatment and other treatment .................................. 37 
6.3.2  Instruction for prescribing and tak ing study treatment ......................... 38 
6.4 Participant numbering, treatment assignment, randomization  .............................. 39 
6.4.1  Participant numbering  ........................................................................... 39 
6.4.2  Treatment assignment, randomization  .................................................. 39 
6.5 Treatment blinding  ................................................................................................ 39 
6.6 Dose escalation and dose modification .................................................................. 40 
6.6.1  Definitions of dose limiting toxicities (DLTs) ...................................... 40 
6.6.2  Dose modifications ................................................................................ 40 
6.6.3  Follow-up for toxicities ......................................................................... 40 
6.7 Additional treatment guidance ............................................................................... 42 
6.7.1  Treatment compliance  ........................................................................... 42 
6.7.2  Recommended treatment of adverse events  .......................................... 42 
6.7.3  Emergency breaking of assigned treatment code  .................................. 42 
7 Informed consent procedures ............................................................................................ 43 
8 Visit schedule and assessments  ......................................................................................... 44 
8.1 Screening  ............................................................................................................... 50 
8.1.1  Information to be collected on screening failures ................................. 50 
8.2 Participant demographics/other baseline characteristics  ....................................... 50 
8.3 Efficacy  .................................................................................................................. 51 
8.3.1  LDL -C ................................................................................................... 51 
8.3.2  Additional efficacy assessments  ........................................................... 51 
8.3.3  Appropriateness of efficacy assessments  .............................................. 51 
8.4 Safety  ..................................................................................................................... 52 
8.4.1  Laboratory evaluations  .......................................................................... 52 
8.4.2  Electrocardiogram (ECG) ..................................................................... 54 
8.4.3  Pregnancy and assessments of fertility  ................................................. 54 
8.4.4  Appropriateness of safety measurements  .............................................. 55 
Novartis  Confidential  Page 4 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
8.5 Additional assessments  .......................................................................................... 55 
8.5.1  Trial Feedback Questionnaire  ............................................................... 55 
  ............................................................................................ 55 
8.5.3  Lifestyle instructions  ............................................................................. 55 
9 Discontinuation and completion ........................................................................................ 56 
9.1 Discontinuation from study treatment and from study  .......................................... 56 
9.1.1  Discontinuation from study treatment  ................................................... 56 
9.1.2  Discontinuation from study  ................................................................... 57 
9.1.3  Lost to follow -up ................................................................................... 57 
9.2 Withdrawal of informed consent/Opposition to use data/biological samples  ....... 57 
9.3 Study completion and post- study treatment  .......................................................... 58 
9.4 Early study termination by the sponsor ................................................................. 59 
10 Safety monitoring, reporting and committees  ................................................................... 59 
10.1  Definition of adverse events and reporting requirements  ...................................... 59 
10.1.1  Adverse events ...................................................................................... 59 
10.1.2  Serious adverse even ts .......................................................................... 61 
10.1.3  SAE reporting........................................................................................ 62 
10.1.4  Pregnancy reporting .............................................................................. 63 
10.1.5  Reporting of study treatment errors including misuse/abuse ................ 63 
10.2  Additional Safety Monitoring  ................................................................................ 64 
10.2.1  Liver safety monitoring  ......................................................................... 64 
10.2.2  Renal safety monitoring  ........................................................................ 64 
10.3  Committees  ............................................................................................................ 65 
11 Data Collection and Database management  ...................................................................... 65 
11.1  Data collection  ....................................................................................................... 65 
11.2  Database management and quality control ............................................................ 65 
11.3  Site monitoring  ...................................................................................................... 66 
12 Data analysis and statistical methods  ................................................................................ 66 
12.1  Analysis sets .......................................................................................................... 66 
12.2  Participant demographics and other baseline characteristics  ................................. 67 
12.3  Treatments  ............................................................................................................. 68 
12.4  Analysis supporting primary objectives ................................................................ 68 
12.4.1  Definition of primary endpoint(s)  ......................................................... 68 
12.4.2  Statistical model, hypothesis, and method of analysis .......................... 69 
12.4.3  Handling of intercurrent events of primary estimands  .......................... 70 
12.4.4  Handling of missing values not related to intercurrent event  ............... 71 

Novartis  Confidential  Page 5 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
12.4.5  Sensitivity analyses  ............................................................................... 71 
12.4.6  Supplementary analysis ......................................................................... 71 
12.5  Analysis supporting secondary objectives ............................................................. 71 
12.5.1  Efficacy and/or Pharmacodynamic endpoint(s) .................................... 71 
12.5.2  Safety endpoints .................................................................................... 73 
  ............................................................................................ 74 
  ......................................................................... 74 
12.7  Interim analyses  ..................................................................................................... 74 
12.8  Sample size calculation .......................................................................................... 75 
12.8.1  Primary endpoint(s)  ............................................................................... 75 
12.8.2  Secondary endpoint(s) ........................................................................... 75 
13 Ethical considerations and administrative procedures  ...................................................... 75 
13.1  Regulatory and ethical compliance ........................................................................ 75 
13.2  Responsibilities of the investigator and IRB/IEC  .................................................. 75 
13.3  Publication of study protocol and results............................................................... 76 
13.4  Quality Control and Quality Assurance  ................................................................. 76 
13.5  Participant Engagement  ......................................................................................... 77 
13.6  Data Protection  ...................................................................................................... 77 
14 Protocol adherence  ............................................................................................................ 77 
14.1  Protocol amendments ............................................................................................. 78 
15 References  ......................................................................................................................... 79 
16 Appendices ........................................................................................................................ 81 
16.1  Appendix 1: Clinically notable laboratory values and vital signs ......................... 81 
16.2  Appendix 2: Liver event and laboratory trigger definitions & follow-up 
requirements .......................................................................................................... 82 
16.3  Appendix 3: Specific Renal Alert Criteria and Actions and Event Follow-up ...... 84 
 
List of tables  
Table 2 -1 Objectives and related endpoints .......................................................... 22 
Table 6 -1 Investigational and control drug ............................................................ 33 
Table 6 -2 Medication allowed under certain conditions ....................................... 35 
Table 6 -3 Prohibited medication  ........................................................................... 36 
Table 6 -4 Dose and treatment schedule  ................................................................. 38 
Table 6 -5 Guidance on clinical and diagnostic assessments to rule out alternative causes of observed LFT abnormalities ................................ 41
 
Table 8 -1 Assessment Schedule  ............................................................................ 46 

Novartis  Confidential  Page 6 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Table 8 -2 Safety assessments  ................................................................................ 52 
Table 8 -3 Safety Laboratory Assessments  ............................................................ 53 
Table 10-1  Guidance for capturing the study treatment e rrors including 
misuse/abuse ......................................................................................... 63 
Table 16-1  Liver laboratory trigger definitions  ....................................................... 82 
Table 16-2  Follow- up requirements for liver laboratory triggers - ALT, AST, 
TBL  ....................................................................................................... 82 
Table 16-3  Follow-up requirements for liver laboratory triggers - Isolated 
Hyperbilirubinemia or elevated ALP .................................................... 83 
 
List of figures  
Figure 3-1  Study Design  ......................................................................................... 24 
Figure 12-1  Testing procedure for primary and secondary endpoints ...................... 73 
 
Novartis  Confidential  Page 7 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
List of abbreviations  
ACC  American College of Cardiology  
ADR  Adverse Drug Reaction  
AE Adverse Event  
AHA American Heart Association  
ALP Alkaline Phosphatase  
ALT Alanine Aminotransferase  
ANA Antinuclear Antibodies  
ANCOVA  Analysis of covariance  
Apo A -1 Apolipoprotein A -1 
Apo B  Apolipoprotein B  
APTT  Activated Partial Thromboplastin time  
ASCVD  Atherosclerotic Cardiovascular Disease  
ASMA  Anti-smooth muscle antibody  
ASO  Antisense Oligonucleotide  
AST Aspartate Aminotransferase  
ATC Anatomical Therapeutic Chemical  
BP Blood pressure  
BUN  Blood Urea Nitrogen  
CD-transferrin  Carbohydrate -deficient transferrin  
CFR Code of Federal Regulations  
CIOMS  Council for International Organizations of Medical Sciences  
CK Creatine Kinase  
cm centimeter(s)  
CMO&PS  Chief Medical Office and Patient Safety  
CMV  Cytomegalovirus  
CO Country Organization  
CRO  Contract Research Organization  
CSR  Clinical study report  
CTIS  Clinical Trials Information System (European Medicines Agency)  
CTT Clinical Trial Team  
CV Cardiovascular  
CVD  Cardiovascular Disease  
DHA  Docosahexaenoic acid  
DILI Drug -Induced Liver Injury  
dL deciliter(s)  
DNA  Deoxyribonucleic acid  
EBV Epstein -Barr virus  
EC European Commission  
ECG  Electrocardiogram  
eCRF  Electronic Case Report/Record Form  
EDC  Electronic Data Capture  
eGFR  Estimated glomerular filtration rate  
EMA  European Medicines Agency  
EOS  End of Study  
EOT End of Treatment  
EPA Eicosapentaenoic acid  
Novartis  Confidential  Page 8 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
ERCP  Endoscopic retrograde cholangiopancreatography  
eSAE  Electronic Serious Adverse Event  
EU European Union  
EudraCT  European Union Drug Regulating Authorities Clinical Trials Database  
FAS Full Analysis Set  
FDA Food and Drug Administration  
FPG Fasting Plasma Glucose  
FSH Follicle Stimulating Hormone  
GalNAc  N-Acetylgalactosamine  
GCP  Good Clinical Practice  
GCS  Global Clinical Supply  
GGT  Gamma -glutamyl transferase  
GLDH  Glutamate Dehydrogenase  
HAV Hepatitis A Virus  
HbA1c  Glycated hemoglobin (hemoglobin A1c)  
HBc Hepatitis B core antigen  
HBsAg  Hepatitis B virus surface antigen  
HBV Hepatitis B Virus  
HCV  Hepatitis C Virus  
HDL-C High-Density Lipoprotein Cholesterol  
HeFH  Heterozygous Familial Hypercholesterolemia  
HEV Hepatitis E Virus  
HSV Herpes simplex virus  
IB Investigator's Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonization (of Technical Requirements for Pharmaceuticals for 
Human Use)  
IEC Independent Ethics Committee  
Ig Immunoglobulin  
IN Investigator Notification  
INR International Normalized Ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
ITT Intent -To-Treat  
IUD Intrauterine Device  
IUS Intrauterine System  
kg kilogram(s)  
LDL-C Low-Density Lipoprotein Cholesterol  
LDLR  Low Density Lipoprotein Receptor  
LFT Liver function test  
LLT Lipid -Lowering Therapy  
Lp(a)  Lipoprotein (a)  
LPLV  Last participant last visit  
MCH  Mean Corpuscular Hemoglobin  
MCHC  Mean Corpuscular Hemoglobin Concentration  
MCP  Multiple Comparison Procedure  
MCV  Mean Corpuscular Volume  
Novartis  Confidential  Page 9 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
MDRD  Modification of diet in renal disease  
MedDRA  Medical dictionary for regulatory activities  
mg milligram(s)  
mL milliliter(s)  
mmol  millimol(s)  
MRI Magnetic resonance imaging  
mRNA  Messenger  ribonucleic acid  
non-HDL-C non-High-Density Lipoprotein Cholesterol  
NYHA  New York Heart Association  
OHP  Off-site Healthcare Professional  
p.o. oral(ly)  
PCE Pooled cohort equations  
PCR  Protein -creatinine ratio  
PCSK9  Proprotein Convertase Subtilisin/Kexin type 9  
PD Pharmacodynamic(s)  
PMM  Pattern -Mixture Model  
PT Prothrombin time  
QMS  Quality Management System  
QTcF  QT interval corrected by Fridericia’s formula  
RAS Randomized Analysis Set  
RDO  Retrieved Drop Out  
RISC  Ribonucleic acid -Induced Silencing Complex  
RNA  Ribonucleic acid  
RNAi  Ribonucleic acid interference  
s.c. subcutaneous(ly)  
SAE Serious Adverse Event  
SAF Safety Analysis Set  
SAP Statistical Analysis Plan  
SARS -CoV-2 Severe  acute respiratory syndrome coronavirus 2 also referred to as COVID -19 
SCR  Screened Set  
siRNA  small interfering ribonucleic acid  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
T3 Triiodothyronine  
T4 Thyroxine  
TBL Total bilirubin  
TC Total cholesterol  
TEAE  Treatment -Emergent Adverse Event  
TFQ Trial Feedback Questionnaire  
TSH Thyroid stimulating hormone  
U/L Units/Liter  
ULN Upper limit of normal  
US United States (of America)  
WHO  World Health Organization  
WoC  Withdrawal of Consent  
Novartis  Confidential  Page 10 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Glossary of terms  
Additional 
treatment  Medicinal products that may be used during the clinical trial as described in the protocol, 
but not as an investigational medicinal product (e.g. any background therapy)  
Assessment  A procedure used to generate data required by the study  
Biologic Samples  A biological specimen including, for example, blood (plasma, serum), saliva, tissue, 
urine, stool, etc. taken from a study participant  
Clinical Trial Team  A group of people responsible for the planning, execution and reporting of all clinical trial 
activities. Examples of team members include the Study Lead, Medical Monitor, Trial 
Statistician etc.  
Coded Data  Personal Data which has been de-identified by the investigative center team by 
replacing personal identifiers with a code.  
Cohort  A group of individuals who share a common exposure, experience or characteristic, or a 
group of individuals followed -up or traced over time  
Control drug  A study drug (active or placebo) used as a comparator to reduce assessment bias, preserve blinding of investigational drug, assess internal study validity, and/or evaluate 
comparative effects  of the investigational drug  
Discontinuation 
from study  Point/time when the participant permanently stops receiving the study treatment and 
further protocol required assessments or follow -up, for any reason. No specific request 
is made to stop the use of their samples or data.  
Discontinuation from study 
treatment  Point/time when the participant permanently stops receiving the study treatment for any 
reason (prior to the planned completion of study drug administration, if any). Participant agrees to the other protocol required assessments including follow -up. No specific 
request is made to stop the use of their samples or data.  
Dosage  Dose of the study treatment given to the participant in a time unit (e.g. 100 mg once a 
day, 75 mg twice a day)  
Electronic Data 
Capture (EDC)  Electronic data capture (EDC) is the electronic acquisition of clinical study data using 
data collection systems, such as Web-based applications, interactive voice response 
systems and clinical laboratory interfaces. EDC inclu des the use of Electronic Case 
Report Forms (eCRFs) which are used to capture data transcribed from source 
data/documents used at the point of care  
End of the clinical 
trial The end of the clinical trial is defined as the last visit of the last participant. 
Enrollment  Point/time of participant entry into the study at which informed consent must be 
obtained. The action of enrolling one or more participants  
Estimand As defined in the International Council for Harmonization (ICH) E9(R1) addendum, 
estimand is a precise description of the treatment effect reflecting the clinical question posed by the trial objective. It summarizes at a population- level what the outcomes 
would be in the same participants under different treatment conditions being compared. Attributes of an estimand include the population, variable (or endpoint) and treatment of 
interest, as well as the specification of how the remaining intercurrent events are 
addressed and a population -level summary for the variable.  
Hybrid Trial Design  A tria l model incorporating both onsite (traditional site based) and offsite (decentralized) 
elements within the same study design.  
Intercurrent events  Events occurring after treatment initiation that affect either the interpretation or the 
existence of the mea surements associated with the clinical question of interest.  
Investigational 
drug/ treatment  The drug whose properties are being tested in the study  
Medication number  A unique identifier on the label of medication kits  
Mis-randomized 
participants  Mis-randomized participants are those who were not qualified for randomization and 
who did not take study treatment, but have been inadvertently randomized into the study 
or the participant allocated to an invalid stratification factor  
Novartis  Confidential  Page 11 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Off-si te Describes any trial activities that are performed at a location that is not the investigative 
site (where the investigator will conduct the trial), such as a home or another appropriate 
location.  
Off-site healthcare 
Professional (OHP) A qualified healthcare professional, including those used in a study e.g. Nurse, 
Phlebotomist, Physician, who performs certain protocol procedures for the participant at 
an off -site location such as a participant's home.  
Other treatment  Treatment that may be needed/allowed during the conduct of the study (i.e. concomitant 
or rescue therapy)  
Participant  A trial participant (can be a healthy volunteer or a patient). "Participant" terminology is 
used in the protocol whereas term "Subject" is used in data collection  
Participant number  A unique number assigned to each participant upon signing the informed consent. This number is the definitive, unique identifier for the participant and should be used to 
identify the participant throughout the study for all data collect ed, sample labels, etc.  
Period The subdivisions of the trial design (e.g. Screening, Treatment, Follow -up) which are 
described in the Protocol. Periods define the study phases and will be used in clinical 
trial database setup and eventually in analysis  
Personal data  Participant information collected by the Investigator that is coded and transferred to Novartis for the purpose of the clinical trial. This data includes participant identifier 
information, study information and biological samples.  
Randomizat ion The process of assigning trial participants to investigational drug or control/comparator 
drug using an element of chance to determine the assignments in order to reduce bias.  
Randomization 
number  A unique identifier assigned to each randomized participant  
Re-screening  If a participant fails the initial screening and is considered as a Screen Failure, he/she can be invited once for a new Screening visit after medical judgment and as specified by 
the protocol  
Remote  Describes any tria l activities performed at a location that is not the investigative site 
where the investigator will conduct the trial, but is for example a home or another 
appropriate location  
Screen Failure  A participant who did not meet one or more criteria that were required for participation in 
the study  
Source 
Data/Document  Source data refers to the initial record, document, or primary location from where data 
comes. The data source can be a database, a dataset, a spreadsheet or even hard-
coded data, such as p aper or electronic source.  
Start of the clinical 
trial The start of the clinical trial is defined as the signature of the informed consent by the 
first participant.  
Study treatment  Any drug or combination of drugs or intervention administered to the study participants as part of the required study procedures; includes investigational drug(s), control(s) or 
background therapy  
Telemedicine  Electronic information and telecommunications technologies (both video-based and audio-only) to facilitate the delivery of health care and health related education where 
participant and investigator and site personnel are not in the same location.  
Treatment 
arm/group  A treatment arm/group defines the dose and regimen or the combination, and may 
consist of 1 or more coho rts. 
Treatment of 
interest  The treatment of interest and, as appropriate, the alternative treatment to which 
comparison will be made. These might be individual interventions, combinations of 
interventions administered concurrently, e.g. as add-on to standard of care, or might 
consist of an overall regimen involving a complex sequence of interventions. This is the 
treatment of interest used in describing the related clinical question of interest, which 
might or might not be the same as the study treatm ent. 
Variable (or endpoint)  The variable (or endpoint) to be obtained for each participant that is required to address 
the clinical question. The specification of the variable might include whether the 
participant experiences an intercurrent event.  
Novartis  Confidential  Page 12 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Withdrawal of study 
consent (WoC)  Withdrawal of consent from the study occurs when the participant explicitly requests to 
stop use of their data and biological samples (opposition to use data and biological 
samples) AND no longer wishes to receive study treatment, AND does not agree to 
further protocol required assessments. This request should be in writing (depending on 
local regulations) and recorded in the source documentation.  
This request should be distinguished from a request to discontinue the study. Other 
study participant's privacy rights are described in the corresponding informed consent 
form (ICF).  
Novartis  Confidential  Page 13 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Amendment 1 (08-Feb-2023 )  
Amendment rationale 
In order to minimize missing data after discontinuation of study treatment, the  amendment 
incorporates  continued efforts to measure endpoints on all participants  until Day 180, even for 
those who may have prematurely discontinued study treatment. 
For regulatory purposes , to provide an estimate of treatment effect under conditions that better  
resemble  clinical practice, the amendment includes a “Treatment -policy Estimand” that  
assesses efficacy of inclisiran in LDL -C lowering irrespective of addition of other LLTs , in 
parallel  to the original  estimand , referred to as “Monotherapy Estimand”, which directly  
evaluates effect  of inclisiran as monotherap y. 
This amendment also incorporates additional guidance for the investigator on lifestyle 
instructions to be given to the pa rticipant s as recommended by the  2019 ACC/AHA Guideline 
on the Primary Prevention of Cardiovascular Disease ( Arnett et al 2019 ). 
In addition, the discontinuation from study treatment criteria are  updated to provide additional 
guidance to the investigator on specific reasons for discontinuation of study treatment includ ing 
liver enzyme elevation and CK criteria, severe and persistent (> 14 days despite appropriate 
treatment) reactions at the injection site and any anaphylactic reactions, and intolerable adverse 
events.  
To avoid unnecessary study treatment discontinuations, the actions taken in response to addition 
of other LLTs  have been updated so that study treatment will not be automatically discontinued 
when other LLTs are taken after randomization  (except for those targeting PCSK9, and RNAi -
based therapies) . 
Finally, minor typos and inconsistencies have been corrected in the protocol . 
As of the date of this amendment, no sites were initiated and no participants were recruited.  
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions. 
The protocol summary  was updated to reflect a ±5 day study window  for the double -blind 
treatment period based on the Day 1 randomization date and a window of +5 days after the Day 
150 visit for the Safety Follow -up / End of Study (EOS) visit. The summary also specifies that 
the last dose of p.o. ezetimibe/placebo will be taken the day before the Day 150 visit. Finally, 
inclusion criterion #4 states that triglycerides will be measured from participants in a fasting 
state, and exclusion criterion #10 was clarified to reflect Secondary hypercholesterolemia e.g., hypothyroid ism (thyroid stimulating hormone (TSH) above the upper limit of normal (ULN)) 
rather than below the lower limit of normal at screening . In the Treatment of Interest Section, 
the additional clarification that treatment of interest is without other LLT was removed. 
Section 2 was updated to add a “Treatment -policy Estimand” that assesses efficacy of inclisiran 
irrespective of addition of other LLTs, in parallel to  the “Monotherapy Estimand”  which is  
Novartis  Confidential  Page 14 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
based on the original estimand but uses the hypothetical strategy to handle discontinuation of 
study treatment instead of the treatment-policy strategy as previously s pecified . 
Section 3 and Figure 3-1 were updated to specify  that participants who prematurely discontinue 
study treatment are expected to continue  to with all planned study visits and be retai ned in the 
study until Day 180 End of Study (EOS) . This section also describes that a  window of ± 5 days 
based on the Day 1 randomization date is allowed for the double-blind treatment period of 150 days. Clarified that safety follow -up/EOS will be conducted 30+5 days after the Day 150 Visit.  
Section 3.3 clarifies that the last dose of p.o. ezetimibe/placebo will be taken by the participant  
on the day before the Day 150 visit. 
In Section 3.4, the visit window is specified as 30 + 5 days after the Day 150 Visit.  
Figure 3-1 inclisiran/pla cebo at the Day 90 post -baseline visit.  Section 9.1.1 is cited to describe 
the circumstances under which study treatment is discontinued.  Section 9.2  is referred to in case 
a subject withdrawals consent and the follow -up actions that are needed by the Investigator. 
Section 5.1 Inclusion criteria  
• Inclusion criterion #4 was updated to clarify that triglycerides will be obtained from 
participant ’s lipids panel in a fasting state . 
Section 5.2 Exclusion criteria  
• Exclusion criterion #10 was clarified  to reflect Secondary hypercholesterolemia e.g., 
hypothyroidism (thyroid stimulating hormone (TSH) above the upper limit of normal 
(ULN) ) rather than below the lower limit of normal at screening. 
• Exclusion criterion #12 specifies Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m
2 at screening will be determined  by the central laboratory using the 
Modification of Diet in Renal Disease (MDRD) formula  
Section 6.1.4, The s afety follow-up / End of Study (EOS) visit window is specified as between 
30 and 35 days after the Day 150 Visit.  
Table 6 -3 Prohibited medication , the prohibited medication table clarifies the prohibition 
periods and actions taken  for the different medication classes , prior to randomization and 
starting from randomization  and throughout the study. Any prohibited medication taken during 
the prohibition period until randomization result in non -randomization of a participant. The 
action taken for other LLTs (except for PCSK9 monoclonal antibodies) starting after 
randomization was modified to have the investigator request the participant to stop the LLTs, 
and to contact Novartis for further guidance.  Investigators should also contact Novartis if the 
participant receives systemic cyclosporine and tacrolimus, systemic steroids, vitamin A derivatives or retinal derivatives for the treatment of dermatologic conditions or antiviral therapies after randomization and until the end of the study.  
Section 6.7.1, added that the treatment compliance for p.o. ezetimibe/placebo should also be 
captured in the appropriate eCRF at each visit  from Visit 2 / Day 30 through Visit 4 / Day150 .  
Section 8 and Table 8 -1 were updated to specify  that participants who prematurely discontinue 
study treatment, are required to complete all planned study visits and be retained until Day 180. 
This section also describes that a window of ± 5 days based on the Day 1 randomization date is 
Novartis  Confidential  Page 15 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
allowed for the double -blind treatment period of 150 days . Day 180 is clarified as occurring 
between 30 + 5 days after the Day 150 Visit 
Table 8 -1 Assessment schedule was updated as follows:  
• HbA1c will be collected at screening  (and not at randomization). 
• Ezetimibe/placebo compliance will be captured in the clinical  database from Day 30 until 
the visit following the last dose of p.o. ezetimibe/placebo .  
• End of Treatment Disposition form will be completed prior to Day 150 for participan ts who 
discontinue study treatment early. 
• Footnote #14 specifies that  if the urinalysis dipstick results are abnormal, then the urine 
sample will be sent to the central laboratory where a macroscopic panel  will be performed 
with a reflexive microscopic panel.  
Section 8.3 specifies that the unblinded lipid panel results will be provided to the Investigator 
and Sponsor at the Screening Visit only.  Table 8 -3, an assessment of HbA1c only has been added at Screening, to ensure that the 
participa nt does not meet the HbA1c exclusion criteri on. The Hematology panel on Day 1 will 
not include a HbA1c measurement.  Urinalysis  and renal follow -up section was updated to 
specify that central lab will perform a macroscopic panel , followed by a reflexive microscopic 
panel.  Section 8.4.2 describes that the baseline ECG is read and interpreted locally by the Investigator 
and any clinically significant abnormalities will be reported on the adverse events CRF.  Section 8.5.3 Lifestyle instructions , were adde d so that i nvestigators can instruct their 
participants  between randomization  and D ay 180 on the ways to prevent ASCVD by promoting 
a healthy lifestyle throughout life. Section 9.1.1, was updated to  clarify that if the participant permanently discontinues p.o. 
ezetimibe/placebo or s.c. inclisiran/placebo, then the participant’s entire  study treatment must 
be stopped. Language has been added to state that participants must be retained in the study 
until Day 180 even if they prematurely discontinue study treatment. To provide the investigator 
with specific examples and to be consistent with prior inclisiran studies, specific liver enzyme 
elevation and CK criteria, language regarding severe and persistent (>14 days despite 
appropriate treatment) reactions at the injection site and any type of anaphylactic reactions, and 
intolerable adverse events are added to the list of discontinuation criteria from study treatment.  
Section 9.3, was updated to clarify that the safety follow -up call or the EOS visit should be 
conducted at least 30 days after the Day  150 visit. 
Section 10.1.1, For a ction taken regarding investigational study drug or comparator, it was 
clarified that t he action taken for ‘D rug I nterrupted ’ is applicable for ezetimibe/placebo only , 
whereas, ‘Dose not C hanged’ and ‘ Permanently D iscontinued’ is applicable to both, study drug 
and comparator drug.  
Section 12.4.2 was updated to reflect the changes in the estimands in Section 2.1. The last 
paragraph of this section was removed in the amendment  because the method described does 
not apply to all the missing values under the new estimands. 
Novartis  Confidential  Page 16 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Section 12.4.3 was updated to describe the strategies used by each of the two estimands  for 
handling intercurrent events.  
Section 12.4.4 was updated to summarize  the methods for imputing missing values not related 
to intercurrent events . 
Section 12.4.5 was updated to include the tipping poi nt analyses to assess the robustness of the 
inferences to various assumptions about the missing data. 
Section 12.4.6 was updated to remove the originally specified supplementary analyses as they 
are no longer necessary or applicable. Section 12.5.1 was updated to reflect the changes in the estimands in Section 2.1. Also, the 
paragraph about missing value imputation was updated to be in line with the strategy for the 
primary endpoints. 
Table 16-2 is updated to be consistent wi th Section 9.1.1 for the liver laboratory triggers and 
action taken.  
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation.  
The changes herein  affect the Informed Consent. Sites are required to update and submit for  
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment. 
Novartis  Confidential  Page 17 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Protocol summary  
Protocol number  CKJX839D12304  
Full Title  A Double-blind, Randomized, Placebo- and Active -Comparator Controlled Study to 
Evaluate the Efficacy of Inclisiran as Monotherapy in Patients with Primary 
Hypercholesterolemia Not Receiving Lipid -Lowering Therapy (VictORION -Mono)  
Brief title  Efficacy and safety of inclisiran as monotherapy in patients with primary 
hypercholesterolem ia not receiving lipid -lowering therapy.  
Sponsor and 
Clinical Phase  Novartis  / Phase III 
Investigation type  Drug  
Study type  Interventional  
Purpose  The purpose of the study is to evaluate the efficacy and safety of inclisiran sodium 300 
mg, administered as monotherapy to participants with primary hypercholesterolemia 
who are not on any lipid -lowering therapy (LLT).  
Primary 
Objective(s)  The primary objectives of the study are:  
● To demonstrate the superiority of inclisiran as monotherapy, compared with placebo,  
in reducing low -density lipoprotein cholesterol (LDL-C) as measured by percentage 
change from baseline to Day  150 
● To demonstrate the superiority of inclisiran as monotherapy, compared with 
ezetimibe, in reducing LDL-C as measured by percentage change from baseline to Day  
150 
Secondary Objectives The secondary objectives of this study are:  
● To assess the efficacy of inclisiran as monotherapy, compared to ezetimibe and 
placebo, on absolute change in LDL- C, percentage change in Proprotein Convertase 
Subtilisin/Kexin type 9 (PCSK9), non-high -density lipoprotein cholesterol (non- HDL-C), 
total cholesterol (TC)/high -density lipoprotein cholesterol (HDL-C) ratio, apolipoprotein B (Apo B), Apo B/apolipoprotein A-1 (Apo A -1) ratio and lipoprotein (a) (Lp(a)) from 
baseline to Day  150 
● To assess the safety and tolerability of inclisiran as monotherapy, compared to 
placebo and ezetimibe.  
Study design  This study is a randomized, double-blind, placebo- and active comparator -controlled, 
multicen ter study in adult participants with primary hypercholesterolemia, not receiving 
any lipid- lowering therapy (LLT) and who have a 10-year Atherosclerotic Cardiovascular 
Disease (ASCVD) risk of less than 7.5%.  
The study consists of:  
● A screening period up to 14 days  
● A double- blind treatment period of 150 ± 5 days  based on the Day 1 randomization 
date; and  
● A Safety Follow -up / End of Study (EOS) visit conducted 30 +5 days after the Day 150 
visit 
All participants who fulfill the inclusion/exclusion criteria will be randomized at baseline 
(Day  1) in a 2:1:1 double-blind fashion to one of three treatment arms:  
● subcutaneous (s.c.) inclisiran and oral (p.o.) placebo (inclisiran arm)  
● s.c. placebo and p.o. ezetimibe (ezetimibe arm)  
● s.c. placebo and p.o. placebo (placebo arm).  
Participants will receive inclisiran sodium 300  mg or placebo by s.c. injection by a 
healthcare professional at the study site on Day  1 and Day  90. Participants will also be 
dispensed oral ezetimibe or placebo on Day  1, Day  30, and Day  90, and will be asked 
to take 1 capsule once a day from Day  1 through the day before the Day  150 visit. 
The overall study duration is approximately 190 days but can vary depending on 
individual screening and the visit windows allowed for the treatment period and EOS 
visit. 
Rationale Statin use up-regulates PCSK9 levels. Therefore, therapies that target PCSK9 may 
perform differently as monotherapy than when added to statin treatment. The study is 
aimed to evaluate the efficacy and safety of inclisiran  sodium 300 mg, administered as 
monotherapy to participants without background lipid -lowering agents, to inform an 
Novartis  Confidential  Page 18 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
understanding of the new PCSK9 inhibition approach with inclisiran and help establish 
efficacy expectations for inclisiran in patient s who cannot take statins.  
Study population  Approximately 300 randomized adult participants (≥  18 to ≤  75 years of age) with 
primary hypercholesterolemia at low risk for their first cardiovascular event (10-year 
ASCVD risk of less than 7.5%), and who are not on any LLT.  
Key Inclusion 
criteria  ● Signed informed consent must be obtained prior to participation in the study  
● Adults ≥  18 to ≤  75 years of age  
● Fasting LDL- C value of ≥  100 mg/dL (equivalent to 2.59 mmol/L) but <  190 mg/dL 
(equivalent to 4.92 mmol/L)  
● Fasting Triglycerides ≤  400 mg/dL (equivalent to 4.52 mmol/L)  
● With a 10-year ASCVD risk score of less than 7.5%, estimated using the pooled 
cohort equations (PCE)  
● Have not been on any LLT within 90 days  
Key Exclusion criteria  ● Use of any LLT within 90 days of screening including statins, ezetimibe, bempedoic 
acid, psyllium preparations,  fibrates, bile-acid sequestrants, PCSK9 monoclonal 
antibodies, red yeast rice, niacin >  200 mg/day, omega- 3 fatty acids [docosahexaenoic 
acid (DHA) and/or eicosapentaenoic acid (EPA), with a total dose >  1000 mg/day], or 
any drug with unknown ingredients taken for the purpose of lipid- lowering, including 
over-the-counter or herbal therapies  
● Use of systemic cyclosporine or tacrolimus, systemic steroids, vitamin A derivatives or 
retinal derivatives for the treatment of dermatologic conditions (vitamin A in a 
multivitamin preparation is permitted), or antiviral therapies (protease inhibitors or direct 
acting antivirals) within 30 days of screening  
● Participants on medications that are known to induce changes in lipids and 
lipoproteins (including but not limited to anticoagulants, loop diuretics, thiazide diuretics, 
beta blockers, amiodarone, estrogens, selective estrogen receptor modulators, 
androgens,  anabolic steroids, and anticonvulsants) unless they are on a stable dose of 
such medications for at least 30 days prior to screening and have no planned dose change or treatment discontinuation during the study duration  
● History of ASCVD (including acute  coronary syndrome, history of myocardial 
infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, 
transient ischemic attack, and peripheral artery disease including aortic aneurysm)  
● Diabetes mellitus or fasting plasma glucose (FPG) at screening ≥  7.0 mmol/L 
(equivalent to 126 mg/dL) or glycated hemoglobin (HbA1c) ≥  6.5% (equivalent to 7.8 
mmol/L or 140 mg/dL)  
● Secondary hypercholesterolemia, e.g., hypothyroidism [thyroid stimulating hormone 
(TSH) above the upper limit of normal ( ULN)] or nephrotic syndrome at screening  
Study treatment Study drug:  
● KJX839 / Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5  mL solution 
for injection  
● Matching s.c. placebo in 1.5 mL solution for injection  
Control drug:  
● Ezetimibe 10 mg p.o.  
● Matching p.o. placebo  
Treatment of 
interest  The randomized 2:1:1 double- blind treatment of:  
● s.c. injections of inclisiran sodium 300 mg and p.o. placebo (inclisiran arm),   
● s.c. injections of placebo and p.o. ezetimibe (ezetimibe arm) or   
● s.c. injections of placebo and p.o. placebo (placebo arm)  
Efficacy assessments  Efficacy assessments (using Central lab) are as follows:  
● LDL-C (primary) 
● PCSK9 
● non-HDL-C 
● TC/HDL-C ratio  
● Apo B  
● Apo B/Apo A -1 ratio  
● Lp(a)  
Key safety 
assessments  Adverse event monitoring (adverse events (AEs) and serious AEs (SAEs), vital signs, 
laboratory parameters (blood, urine)  
Novartis  Confidential  Page 20 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
1 Introduction  
1.1 Background 
The prevalence of atherosclerotic cardiovascular disease (ASCVD) is increasing in many 
countries due to an aging population combined with atherogenic lifestyles. Mortality from ASCVD has been declining in most developed countries as a result of improvement in risk  
management and clinical intervention. However, ASCVD remains the leading cause of death among chronic diseases. Cardiovascular disease (CVD) results in over 17 million deaths 
annually ( WHO 2021). ASCVD continues to be the most important health issue in the 
developed world and has also become one of the most pressing health problems in developing countries in the past decade. 
High blood cholesterol is a major risk factor for ASCVD. Reduc tion in Low -Density 
Lipoprotein Cholesterol (LDL -C) levels have been shown to reduce subsequent cardiovascular 
events, for both primary and secondary prevention of ASCVD. Current consensus statements 
recommend consideration of an aggressive treatment goal of LDL -C less than 70  mg/dL  
(1.8 mmol/L) for high risk or very high risk patients.  
Despite the success of statin therapy, significant gaps remain in the treatment of hypercholesterolemia. Many patients on statin regimens still experience complications of atherosclerosis. Others have persistently high LDL -C levels due to severe forms of 
hypercholesterolemia, poor tolerability of available medications, or persistent non-compliance to available medications due to complex reasons such as behav ioral, psychological, and 
educational factors. For these populations, new effective lipid -lowering therapies (LLT) that 
impose less medication administration burden and improve compliance may offer significant clinical benefits (Assmann  et al 2006, Banach  et al 2016, Fox  et al 2018 ). 
The hepatic cell  surface low -density lipoprotein receptor (LDLR) plays an essential role in 
plasma clearance of circulating LDL -C and in whole body cholesterol homeostasis, while 
proprotein convertase subtilisin/kexin type 9 (PCSK9) is instrumental in recycling and regula tion of LDLR (Brown  and Goldstein  2006 , Horton et  al 2007). PCSK9 is expressed and 
secreted into the bloodstream predominantly by the liver. It binds to the LDLR both intracellularly and extracellularly, promotes the lysosomal degradation of these receptors in hepatocytes ( Lakoski et al 2009, Mousavi et  al 2009), and consequently increases the 
circulating LDL -C levels. The inhibition of PCSK9 offers an effective approach to lower  
LDL -C. 
The inhibition of PCSK9 can be achieved by PCSK9 -binding monoclonal antibodies that 
prevent the interaction of PCSK9 with LDLR. PCSK9 -binding monoclonal antibodies have 
shown to reduce LDL -C by 55- 65% ( Sabatine et  al 2017, Schwartz et  al 2018). These PCSK9 
monoclonal antibodies require an injection frequency of every 2 to 4 weeks, necessitating up to 26 injections per year ( Navarese et  al 2015, Zhang  et al 2015), which leads to a significant 
medication administration burden on patients. 
The inhibition of PCSK9 can also be  achieved by small interfering RNA (siRNA) that can 
selectively and catalytically silence the translation of messenger ribonucleic acids (mRNAs) to 
reduce the intracellular synthesis of PCSK9 protein. Inclisiran (KJX839) is a chemically modified double -stranded siRNA, conjugated on the sense strand with triantennary   
Novartis  Confidential  Page 21 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
N-Acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, the 
antisense strand is incorporated in the RNA -induced silencing complexes (RISC) and directs 
catalytic breakdown of mRNA for PCSK9. This then leads to the inhibition of the synthesis of 
PCSK9 protein. Reduced intrahepatic PCSK9 increases LDL -C receptor recycling and 
expression on the hepatocyte cell surface, which ultimately improves LDL -C uptake and lowers 
LDL -C levels in the circulation (Fitzgerald  et al 2017). This novel mechanism has been proven 
to be effective.  In the ORION-9, - 10, and - 11 Phase III studies, treatment with inclisiran  
sodium 300 mg administered by subcutaneous (s.c.) injection on Day 1, Day 90 and every  
6 months thereafter, resulted in placebo- adjusted percentage reductions in LDL -C from baseline 
to Day 510 of 48% to 52%, with time -adjusted average reductions of 44% to 54% over  
18 months in participants with ASCVD, ASCVD risk equivalent, and/or heterozygous familial hypercholesterolemia (HeFH) ( Raal et al 2020 , Ray et al 2020). There were no clinically 
relevant differences in the safety profile of inclisiran compared with placebo, except for a higher incidence of treatment -emergent adverse events (TEAEs) at the injection site with inclisiran in 
these Phase III trials. AEs at the injection site were localized, mild and transient in nature. Inclisiran is not associated with an increased risk for hepatic or renal dysfunction, hypersensitivity, neurologic events and neurocognitive disorders, or ophthalmological events and there is no difference from placebo in new onset or worsening of diabetes. The potential for immunogenicity of inclisiran is low.  
The long- term safety of inclisiran has been observed in two safety extension studies ORION -8 
(the extension study of ORION -9, -10 and - 11) and ORION- 3 (the extension study of the Phase 
II trial ORION -1). The overall safety profile observed in ORION -8 and ORION- 3 was similar 
to that reported in inclisiran -treated participants of its feeder studies (ORION-9, - 10, and -11; 
ORION- 1). The favorable safety profile for inclisiran remains unaltered in light of the additional 
longer- term safety data from ORION -8 and - 3. Additional details on the efficacy and safety of 
inclisiran are available in the Invest igator’s Brochure (IB).  
1.2 Purpose 
The purpose of the study is to evaluate the efficacy and safety of inclisiran sodium 300 mg, 
administered as monotherapy to participants with primary hypercholesterolemia who are not on any LLT. This selected, not-on- treatment population allows for an assessment of the treatment 
effects and safety of inclisiran in the absence of confounding factors, such as statin intolerance 
or concomitant treatment with other LLT such as statins or ezetimibe. For ethical reaso ns related 
to conducting a placebo- controlled study in which some participants would receive no active 
anti-hyperlipidemia treatment, this trial will enroll patients with low cardiovascular risk who 
do not require cholesterol lowering therapy per treatment guidelines. 
Novartis  Confidential  Page 22 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
2 Objectives, endpoints and estimands  
Table 2-1 Objectives and related endpoints 
Objective(s)  Endpoint(s)  
Primary objective(s)  Endpoint(s) for primary objective(s)  
● To demonstrate the superiority of inclisiran as 
monotherapy, compared with placebo,  in reducing 
LDL-C as measured by percentage change from 
baseline to Day 150  ● Percentage change in LDL- C from baseline to  
Day 150  
● To demonstrate the superiority of inclisiran as 
monotherapy, compared with ezetimibe, in reducing 
LDL-C as measured by percentage change from 
baseline to Day 150  ● Percentage change in LDL- C from baseline to  
Day 150  
Secondary objective(s)  Endpoint(s) for se condary objective(s)  
● To assess the efficacy of inclisiran as monotherapy, 
compared to ezetimibe and placebo, on absolute change in LDL- C, percentage change in PCSK9, non-
HDL-C, TC/HDL-C ratio, Apo B, Apo B/Apo A -1 ratio 
and Lp (a) from baseline to Day 1 50 ● Absolute change in LDL-C, percentage change in 
PCSK9, non- HDL-C, TC/HDL -C ratio, Apo B,  
Apo B/Apo A -1 ratio and Lp (a) from baseline to  
Day 150  
● To assess the safety and tolerability of inclisiran as 
monotherapy, compared to placebo and ezetimibe  ● Incidence of TEAEs and SAEs, safety laboratory 
values at each visit  
2.1 Primary estimands  
The estimand is the precise description of the treatment effect and reflects strategies to address 
events occurring during trial conduct which could impact the interpretation of the trial results (e.g., premature discontinuation of treatment). 
There will be two estimands of interest in comparing efficacy of inclisiran as monotherapy 
against that of placebo or ezetimibe: a “Monotherapy Estimand” and a “Treatment -policy 
Estimand”.  
For the “Monotherapy Estimand,” t he clinical question of primary interest is: what is the 
reduction in LDL -C, quantified by difference of mean percentage changes from baseline to Day  
150, in trial participants with primary hyper cholesterolemia and a 10- year ASCVD risk of less 
than 7.5% who are not on any LLT, and receive inclisiran as monotherapy, compared to the reduction in those who are on placebo or ezetimibe, if participants had not died or discontinued 
study treatments, and if other lipid -lowering therapy were not available. 
The justification for the Monotherapy E stimand is that it will capture the effect of inclisiran as 
monotherapy in reducing LDL -C, in line with the study purpose of assessing the treatment 
effects of inclisiran in the absence of confounding factors such as concomitant treatment with other LLTs . 
The Monotherapy E stimand  is described by the following attributes: 
Population: Participants with primary hypercholesterolemia  and a  10-year ASCVD risk of less 
than 7.5%, who are not on any LLT. ASCVD risk will be estimated using the Pooled Cohort 
Equations (PCE) ( Grundy et  al 2019).  
Endpoint: Percentage change from baseline to Day  150 in LDL -C. 
Novartis  Confidential  Page 23 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Treatments of interest: Inclisiran as monotherapy compared to the use of comparator (placebo 
or ezetimibe).  
Handling of intercurrent events:  
• Information following permanent discontinuation of study treatment will be handled with a hypothetical scenario of what would happen if the participants had not prematurely discontinued any study treatment (hypothetical strategy) . 
• Participants who died will be handled in a hypothetical scenario of what would have happened had they not died (hypothetical strategy ). 
• Use of other LLT will be treated in a hypothetical scenario of what would happen if other LLT were not available (hypothetical strategy).  
Summary measure: The summary measure to be used is the difference of mean percentage changes.  
In addition, for regu latory purposes, t he “Treatment -policy Estimand” was added in parallel as 
a primary estimand. This estimand shares the same population, endpoint, and summary measure as the Monotherapy Estimand but considers different treatments of interest and adopts alternative strategies for handling intercurrent events:  
Treatments of interest: Inclisiran as monotherapy compared to the use of comparator (placebo or ezetimibe) with or without other LLTs added during the study. 
Handling of intercurrent events:  
• Permanent discontinuation of study treatment will be ignored (treatment- policy strategy).  
• Death will be handled as an unfavorable outcome using a composite variable strategy. 
• Use of other LLTs will be ignored (treatment -policy strategy).  
The Treatment -policy Estimand  answers the clinical question regarding inclisiran efficacy in 
LDL -C lowering as compared to placebo or ezetimibe irrespective of adherence to study drug 
or addition of other LLTs, with death being an unfavorable outcome.  Complete details on the statistical methods and inference, including missing data handling and 
sensitivity analyses are provided in Section  12.4 . 
2.2 Secondary estimands  
The secondary estimands address the same clin ical question as the primary estimands, albeit for 
different endpoints.  For each of the secondary efficacy endpoints, the Treatment -policy 
Estimand and the Monotherapy Estimand will be defined in a similar way as for the primary endpoint. They share the same population, strategies for handling intercurrent events, summary 
measure, as well as the same treatments of interest as the primary estimand s. They differ by the 
definition of the endpoints, these being: 
• Absolute change in LDL- C from baseline to Day  150 
• Percentage change in PCSK9, non- HDL -C, TC/HDL -C ratio, Apo B, Apo B/Apo  A-1 
ratio and Lp(a) from baseline to Day  150 
The statistical methods and inference approaches are described in  Section  12.5. 
Novartis  Confidential  Page 24 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
3 Study design  
This study is a randomized, double -blind, placebo - and active comparator -controlled, 
multicenter study in adult participants with primary hypercholesterolemia not receiving any 
LLT and who have a 10- year ASCVD risk of less than 7.5%, estimated using the PCEs 
(Grundy et  al 2019). This study will evaluate the efficacy and safety of inclisiran sodium  
300 mg, administered as a monotherapy in comparison to ezetimibe and placebo.  
The study design is depicted in Figure 3-1. The study consists of: 
• a screening period of up to 14 days; 
• a double-blind treatment period of 150 ± 5 days based on the Day 1 randomization date ; 
and 
• a safety follow -up / End of Study (EOS) visit conducted 30 +5 days after the Day 150 
Visit  
The overall study duration is approximately 190 days but can vary depending on individual 
screening and the visit windows allowed for the treatment pe riod and EOS visit. 
Figure 3-1 Study Design 
 
3.1 Off-site procedures  
At the investigator's direction and based on benefit -risk considerations of the participant's 
clinical condition, qualifying participants may be offered the option to have certain clinical trial procedures performed at an off -site location, as defined in Table  8-1. A hybrid model is planned 
for this study incorporating both onsite and off -site visits. The off -site procedures will be 

Novartis  Confidential  Page 25 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
utilized in certain countries and sites as determined by protocol needs and based on national 
and local/site regulations . 
One or more of the following elements may be implemented to support off -site visits where 
allowed by national and local regulations: 
• Telemedicine  
• Off-site healthcare professional (OHP)  
• Direct -to-participant shipment of study supplies  
• Direct -to-participant shipment of study treatment (i.e., oral ezetimibe/placebo, refer to 
Section  6.3) 
3.1.1 Responsibility of Investigators 
Procedures that are performed off -site remain under the oversight of the investigator, who 
retains accountability for the conduct of all safety and efficacy assessments delegated to an 
OHP, and will ensure the rights, safety and wellbeing of participants. This in cludes the 
following (including, but not limited to): 
• the identification, management and reporting of AEs and SAEs are performed in 
accordance with the protocol and applicable regulations  
• OHPs have appropriate qualifications, training, and experience to successfully conduct off-site procedures  
• source data collected off -site are reviewed and evaluated in a timely manner  
• the investigator or delegate is available to be contacted by the OHP if any issues or concerns are noted during an off- site visit  
• where relevant, the investigator or delegate will be present via telemedicine for a portion of the off- site visit to support the physical examination  
3.1.2 Responsibility of OHPs  
OHPs must have the required qualifications, training, and experience to conduct off -site 
assessments. OHPs are responsible to conduct delegated assessments and collect relevant data at off- site visits in accordance with the clinical trial protocol, International Council for 
Harmonization (ICH) Good Clinical Practice (GCP) guidelines, and national and local regulations and guidelines. 
The OHPs  will be provided by a third- party vendor sourced by Novartis. Where a site wishes 
to use OHPs that are not provided by Novartis this must be agreed with Novartis before use. Any issues or safety concerns ident ified by the OHP will be promptly communicated to the 
investigator or delegate according to a pre -defined communication plan.  
3.1.3 Telemedicine 
The sponsor has qualified and contracted a third- party vendor to provide telemedicine platform 
technology for this st udy. The selected platform is a validated system complying with relevant  
ICH E6 GCP guidelines ( ICH E6  Guideline 2017). Trial participants can interact with site 
Novartis  Confidential  Page 26 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
personnel using online c ommunication tools built into the platform, enabling the following 
capabilities:  
• Secure videoconferencing which allows the participant, OHP and site personnel to be 
connected  
• Reminders to be automatically sent to participants (e.g. visit or dosing reminders)  
3.2 Screening  
At screening, participants will sign the Informed Consent Form (ICF) and their eligibility will be assessed through the review of study inclusion/exclusion criteria. The ICF must be signed before initiation of any study -specific procedures and assessments (see Section  5.1 and 
Section  7 for details).  If at the time of ICF signature the participant is not fasting, he/she will 
have to return for the blood draw in a fasting state. 
During the screening visit, the participant’s individual 10- year ASCVD risk will be estimated  
using the PCEs, an algorithm derived from five prospective community -based studies 
representing a broad spectrum of the US -population as described in the multi -society guideline 
on the management of blood cholesterol ( Grundy et al 2019 ). 
The investigator must ensure that each participant has not been treated with LLT or other 
prohibited medications (see  Table  6-3) for at least 90 days prior to the screening visit. If the 
participant is on any of the permitted concomitant medications (see Table  6-2) known to induce 
lipid and lipoprotein changes, the dose of such medications must have been stable for ≥ 30 days prior to the screening visit with no plan to change the dose or to discontinue during the study duration. 
The screening period can be up to 14 days to allow adequate time for the completion of all 
qualifying screening and eligibility evaluations and potentially repeating some of the screening evaluations (e.g., laboratory results), as applicable (see Section  8.1). A participant who enters 
screening and is determined not eligible during the screening period or at the time of randomization will be considered a screen failure.  
3.3 Double -blind treatment  
Baseline visit  
All participants who fulfill the inclusion/exclusion criteria (Section  5.1 and Section  5.2) will be 
randomized at baseline (Day  1) in a 2:1:1 double -blind fashion to one of three treatment arms: 
s.c. inclisiran and p.o. placebo (inclisiran arm); s.c. placebo and p.o. ezeti mibe (ezetimibe arm); 
or s.c. placebo and p.o. placebo (placebo arm). Participants will be stratified by their screening LDL -C result (LDL -C ≤ 130 mg/dL vs. LDL -C > 130 mg/dL). Following randomization at the 
Baseline visit (Day  1), the participant will rec eive inclisiran sodium 300 mg or placebo by 
subcutaneous injection by a healthcare professional at the study site. The participant will also be dispensed one bottle of oral ezetimibe or placebo, and will be asked to take 1 capsule once a day, starting with  the day of the Baseline visit (Day 1). 
Novartis  Confidential  Page 27 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
At the Baseline visit, all participants will be instructed to comply with lifestyle changes 
according to clinical guidelines (Grundy et  al 2019), and these instructions will be reinforced at 
every visit.  
Post -Baseline visits  
Following the Baseline visit, participants will have study visits on Day 30, Day 90, and Day  
150. The  participant will receive a second subcutaneous injection of 300  mg inclisiran sodium 
or placebo on Day 90  
(Figure 3-1), administered by a healthcare professional  at the  study site. The participant will 
also be dispensed oral ezetimibe or placebo on Day  1, Day 30, Day 90 and will be asked to 
continue to take 1 capsule once a day from Day 1 through the day before the Day 150 visit. 
Please refer to  Section  9.1.1 for reasons for early discontinuation of study treatment and the 
study procedures to follow. Section  9.2 provides instructions in case a participant with draws 
informed consent. 
3.4 Safety Follow -up/EOS 
The End of Study (EOS) visit (Day 180) will be the safety follow -up conducted 30 +5 days 
after the Day 150 visit. No data beyond EOS will be collected in the electronic Case Report Form (eCRF). If a participant discontinues from the study early, the investigator must do their best to ensure that the participant returns for an EOS visit. 
4 Rationale  
4.1 Rationale for study design  
Statin use up- regulates PCSK9 levels. Therefore, therapies that target PCSK9 may perform 
differently as monotherapy than when added to statin treatment. The study is aimed to evaluate 
the efficacy and safety of inclisiran  sodium 300 mg, administered as monotherapy to 
participants without background LLT, to inform an understanding of the new PCSK9 inhibition approach with inclisiran and help establish efficacy expectations for inclisiran in patients who cannot take statins.  
LLT is not required per American Heart Association (AHA)/American College of Cardiology (ACC) primary prevention guidelines in patients with primary hypercholesterolemia who have a low 10- year ASCVD risk (< 5%) or a borderline risk (5% to <  7.5%) without risk enhancers 
if the participants have LDL -C measured less than 190  mg/dL ( Arnett et al 20 19,  
Grundy et al 2019). This trial is designed to be conducted in this population, in order to remove confounding by statin use or a history of statin intolerance, and to meet ethical requirements. 
4.1.1 Rationale for choice of background therapy 
The participants must fulfill the requirement of not being on any lipid -lowering background 
therapy within 90 days prior to the screening and throughout the study. The purpose is to remove 
any potential confounding effect caused by statin intolerance or con comitant LLT such as 
statins or ezetimibe, in the monotherapy setting. 
Novartis  Confidential  Page 28 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
4.2 Rationale for dose/regimen and duration of treatment  
A Phase II study (ORION -1) has shown that 300 mg dose of inclisiran sodium administered as 
one or two doses is the lowest dose to achieve near‑maximal reductions in PCSK9 (70.9% and 
74.5%, respectively) and LDL‑C (50.9% and 59.7%, respectively) levels. Three Phase III 
studies (ORION-9, - 10, and - 11) in adults with ASCVD, ASCVD risk equivalents and/or HeFH  
demonstrated that 300  mg inclisiran sodium s.c. on Day 1, Day 90 and every 6 months thereafter 
resulted in placebo -adjusted percentage reductions in LDL -C from baseline at Day  510 of 50% 
to 58%, with time -adjusted average reductions of 44% to 54% sustained over 18 months. In 
these stud ies, this dose also showed good tolerability of inclisiran, with a safety profile similar 
to placebo, except for a higher incidence of AEs at the injection site. Based on nonclinical and clinical data, including Phase I, II and III clinical studies as well as pharmacodynamic (PD) 
modeling in adult participants, the same dose will be used in the present study. The inclisiran dose and regimen in the study is 300 mg s.c. administered at Baseline and Day 90. This is the 
approved dose by the United States Food and Drug Administration (FDA) and in the European Union (EU). 
ORION- 1 also demonstrated that two injections on Day 1 and on Day 90 produced a significant 
percentage LDL -C reduction of 52.6% at Day 180. In ORION -9, -10, and - 11, two initial 
injections (Day  1 and Day 90) led to a similar percentage reduction in LDL -C at Day  150. The 
magnitude of this reduction was then maintained with subsequent injections every 6 months. 
Based on these data, a 6 -month study duration with two injections of blinded study medica tion 
is deemed as sufficient for observing the effect of inclisiran as a monotherapy, compared to placebo and ezetimibe. In addition, this duration will leave placebo- treated participants with the 
shortest unprotected period of no LLT as participants' lipid- lowering need may change 
following the study enrollment.  
4.3 Rationale for choice of control drugs (comparator/placebo)  
A placebo -controlled arm is a standard design in drug development to assess efficacy and safety 
and ensures that differences in outcome will be a reliable and realistic measure of the treatment effect of inclisiran. The use of placebo as a comparator is justified as the trial population has a 10-year ASCVD risk of less than 7.5% and does not need to be on any LLT per AHA/ACC 
primary prevention guidelines ( Arnett et al 2019 ). 
The monotherapy use of inclisiran is anticipated mostly in participants who do not tolerate statins well or are unwilling to take a statin due to thei r concerns on the side effects of statins. 
The current non- statin treatment options include ezetimibe, fibrates and nicotinic acid, used 
alone or in combination. Ezetimibe, an intestinal cholesterol absorption inhibitor, is the most commonly used non- statin therapy that selectively inhibits the intestinal absorption of 
cholesterol and related phytosterols. Therefore, it is reasonable to use ezetimibe as an active comparator, in addition to a placebo arm. 
4.4 Purpose and timing of interim analyses/design adaptat ions 
There are no planned interim analyses or design adaptations.  
Novartis  Confidential  Page 29 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
4.5 Risks and benefits  
In general, the risk of participants in this trial may be minimized by compliance with the 
eligibility criteria and study procedures, and close clinical monitoring of safe ty parameters.  The 
risk is further reduced by a minimal study duration of approximately 6 months.  Participants are 
not anticipated to be exposed to greater risks when participating in off -site assessments. OHPs 
will perform assessments for sites participating in the hybrid trial model according to the protocol and study manuals for onsite visits wherever possible, thus data integrity is also expected to be comparable to onsite assessments. Safety management in an off -site setting will 
adhere to the same qua lity standards as for the traditional onsite model and remains under the 
responsibility of the investigator (refer to  Section  3.1.1).  
Women of child -bearing potential must be informed that taking the study treatment may involve 
unknown risks to the fetus if pregnancy were to occur during the study, and agree that in order to participate in the study they must adhere to the contraception requirements outlined in the exclusion cr iteria. If there is any question that the participant will not reliably comply, they 
should not be entered or continue in the study. 
In non- clinical toxicity studies, inclisiran was not carcinogenic or genotoxic. There was no 
effect on paternal performance , spermatogenesis, estrous cycle, and uterine or ovarian 
parameters. Inclisiran did not show evidence of embryolethality, fetotoxicity, or teratogenicity. 
In addition, there were no effects of inclisiran on the development of the F1 generation, including survival, growth, physical and reflexological development, behavior, and reproductive performance. 
The overall clinical experience with inclisiran includes the following completed studies:  
• Three completed Phase I studies; ALN -PCSSC -001 in participants with elevated LDL -C, 
ORION- 6 in participants with mild to moderate hepatic impairment, and ORION -7 in 
participants with renal impairment (mild, moderate, severe)  
• Two completed Phase II studies; ORION -1 in participants with ASCVD or ASCVD risk 
equivalent, and OR ION- 2 in participants with homozygous familial hypercholesterolemia  
• Three completed Phase III studies; ORION -9, -10, and - 11 in participants with HeFH, 
ASCVD or ASCVD risk equivalents  
The safety profile of inclisiran in clinical studies is well characteriz ed and based on data 
obtained from 3 large pivotal trials (ORION -9, -10, - 11) that included 1,833 participants treated 
with inclisiran for up to 18 months ( Wright et  al 2021) and was gen erally comparable to placebo. 
The only inclisiran -related adverse drug reaction (ADR) identified in clinical studies was a 
higher incidence of TEAEs at the injection site, including injection site erythema, injection site 
hypersensitivity, injection site pruritus, injection site rash, and injection site reaction. All 
TEAEs at the injection site were localized, mild or occasionally moderate, transient and resolved without sequelae. The impact of this side effect is further mitigated by the infrequent dosing regimen of inclisiran.  
In Phase III studies (ORION -9, -10, - 11) in participants with HeFH, ASCVD or ASCVD risk 
equivalents, inclisiran administered  on Day  1, Day 90 and every 6 months thereafter lowered 
LDL -C by approximately 50% or more versus placebo in participants on maximally tolerated 
statin therapy with or without other LLT (Raal  et al 2020, Ray  et al 2020 ). 
Novartis  Confidential  Page 30 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
It is widely recognized that LDL -C plays a major role in the initiation and progression of 
ASCVD, and accumulated exposure of elevated LDL -C is causally related to the development 
of ASCVD. As the degree and duration of exposure to elevated LDL -C levels increases the 
atherosclerotic burden, early treatment of hypercholesterolemia in primary prevention is 
essential to the prevention of ASCVD events. The participants in this trial have a 75% chance of being randomized to a LLT (inclisiran or ezetimibe). In addition to the potential reduction in LDL -C, the benefit a participant may have by participating in this study is the opportunity to 
learn more about primary hypercholesterolemia and how to reduce future progression to clinical ASCVD and prevention of ASCVD events.  
4.6 Rationale for planned off -site procedures  
Off-site procedures are planned in this study to minimize burden on participants, and offer them 
increased flexibility to participate in the study from an off- site location (as described in 
Section  3.1 and defined in Table  8-1). This has the potential to broaden access to clinical trials 
for both participants and investigat ors. The hybrid approach will allow participants to maintain 
contact with investigator, both in person during clinic visits at site and through the telemedicine platform during off- site participation.  
4.7 Rationale for Public Health Emergency mitigation procedures  
In addition to the planned off -site procedures, in the event of a Public Health emergency as 
declared by Local or Regional authorities i.e. pandemic, epidemic or natural disaster, additional mitigation procedures to ensure participant safety and trial  integrity may be implemented. If 
allowable by a local Health Authority and depending on operational capabilities, phone calls, virtual contacts (e.g. tele consult) or additional visits by OHPs to the participant's home, can replace onsite study visits (in  addition to the already planned off -site visits), for the duration of 
the disruption until it is safe for the participant to visit the site again.  
Notification of the Public Health emergency should be discussed with Novartis prior to implementation of mitigation procedures, and permitted/approved by Local or Regional Health Authorities and Ethics Committees as appropriate.  
5 Study Population  
The study population consists of approximately 300 randomized adult  participants ( ≥  18 to  
≤ 75 years of age) with primary hypercholesterolemia (fasting LDL -C ≥ 100 mg/dL but  
< 190 mg/dL) at low risk for their first cardiovascular event (10 -year ASCVD risk score of  
< 7.5%), and who are not receiving any LLT.  
5.1 Inclusion criteria  
Participants eligible  for inclusion in this study must meet all  of the following criteria at 
screening:  
1. Signed informed consent must be obtained prior to participation in the study 
2. Adults ≥  18 to ≤  75 years of age 
3. Fasting LDL- C value of ≥  100 mg/dL (equivalent to 2.59 mmol/L) but < 190 mg/dL 
(equivalent to 4.92 mmol/L)  
Novartis  Confidential  Page 31 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
4. Fasting t riglycerides ≤ 400  mg/dL (equivalent to 4.52 mmol/L)  
5. With a 10- year ASCVD risk score of less than 7.5%, estimated using the pooled cohort 
equations (PCE) 
6. Have not been on any lipid-lowering therapy within 90 days 
5.2 Exclusion criteria 
Participants meeting any of the following criteria are not eligible for inclusion in this study.  
1. Use of any lipid-lowering therapy within 90 days of screening including statins, ezetimibe, 
bempedoic acid, psyllium preparations, fibrates, bile -acid sequestrants, PCSK9 
monoclonal antibodies, red yeast rice, niacin > 200 mg/day, omega- 3 fatty acids (DHA 
and/or EPA, with a total dose > 1000 mg/day), or any drug with unknown ingredients taken for the purpose of lipid-lowering, includ ing over -the-counter or herbal therapies  
2. Use of systemic cyclosporine or tacrolimus, systemic steroids, vitamin A derivatives or retinal derivatives for the treatment of dermatologic conditions (vitamin A in a multivitamin preparation is permitted), or antiviral therapies (protease inhibitors or direct acting antivirals) within 30 days of screening  
3. Participants on medications that are known to induce changes in lipids and lipoproteins (including but not limited to anticoagulants, loop diuretics, thiazide diuretics, beta 
blockers, amiodarone, estrogens, selective estrogen receptor modulators, androgens, anabolic steroids, and anticonvulsants) unless they are on a stable dose of such medications for at least 30 days prior to screening and have no planned dose change or treatment discontinuation during the study duration 
4. History of ASCVD (including acute coronary syndrome, history of myocardial infarction, 
stable or unstable angina, coronary or other arterial revascularization, stroke, transient 
ische mic attack, and peripheral artery disease including aortic aneurysm) 
5. Diabetes mellitus or fasting plasma glucose at screening ≥  7.0 mmol/L (equivalent to  
126 mg/dL) or HbA1c ≥  6.5% (equivalent to 7.8 mmol/L or 140  mg/dL) 
6. New York Heart Association (NYHA) class III or IV heart failure or last known left ventricular ejection fraction < 30% at screening.  
7. Uncontrolled severe hypertension: systolic blood pressure (BP) > 160 mmHg or diastolic 
BP >  100 mmHg at screening despite antihypertensive therapy, confirmed with a repeat 
measurement  
8. Uncontrolled serious cardiac arrhythmia (recurrent and highly symptomatic ventricular 
tachycardia, atrial fibrillation, or supraventricular tachycardia) within 90  days prior to 
randomization that is not control led by medications  
9. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 3 x the upper limit of normal (ULN), or total bilirubin 
(TBL) >  2 x ULN at screening  
10. Secondary hypercholesterolemia, e.g., hypothyroidism (thyroid stimulating hormone (TSH) above the upper limit of normal (ULN)) or nephrotic syndrome at screening 
11. Malignancy (except non -melanoma skin can cers, cervical in -situ carcinoma, breast ductal 
carcinoma in situ, or stage 1 prostate carcinoma) within 5 years prior to randomization  
Novartis  Confidential  Page 32 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
12. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 at screening  as 
determined by the central lab oratory  using the Modification of Diet in Renal Disease 
(MDRD) formula  
13. Pregnant or nursing (lactating) women 
14. Women of child-bearing potential, defined as all women physiologically capable of 
becoming pregnant unless they are using effective methods of contraception during dosing 
of study treatment. Effective contraception methods include:  
• Total abstinence (when this is in line with the preferred and usual lifestyle of the 
participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.  
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking investigational dr ug. In case of oophorectomy alone, only when the 
reproductive status of the woman has been confirmed by the follow- up hormone level 
assessment.  
• Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant.  
• Barrier methods of contraception: Condom or Occlusive cap (e.g., diaphragm or cervical/vault caps).  
• Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <  1%), for example hormone vaginal ring or transdermal hormone 
contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS).  
• In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.  
Women are considered post -menopausal if they have had 12 months of natural 
(spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms). Women are considered not of child bearing potential if they are 
post-menopausal or have had surgical bilateral oophorectomy (with or without 
hysterectomy), total hysterectomy or bilateral tub al ligation at least six weeks ago. In the 
case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential. 
If local regulations are more stringent than the contraception methods listed above to 
prevent pregnancy, local regulations apply and will be described in the informed consent 
form (ICF).  
15. Use of any RNAi -based therapeutics, including but not limited to siRNA or Antisense 
Oligonucl eotide (ASO) Therapies within 5 half -lives or 30 days whichever is longer, prior 
to screening 
16. Participation in another investigational device or drug study currently, or within 5 half-lives (if drug) or 30 days whichever is longer, prior to screening 
17. Known  history of alcohol and/or drug abuse within the past 5 years prior to randomization 
Novartis  Confidential  Page 33 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
18. Severe concomitant disease that carries the risk of reducing life expectancy to less than 2 
years  
19. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to 
• Unlikely to understand or comply with the protocol requirements, instructions, and study- related restrictions  
• Have any medical or surgical condition, which in the opinion of the investigator would put the participant at increased risk from participating in the study  
• Persons directly involved in the conduct of the study 
6 Treatment 
6.1 Study treatment  
Participants will be randomized 2:1:1 to double -blind s.c. injections of inclisiran sodium  
300 mg and p.o. placebo (inclisiran arm); s.c. injections of placebo and p.o. ezetimibe 
(ezetimibe arm); or s.c. injections of placebo and p.o. placebo (placebo arm). 
6.1.1 Investigational and control drugs 
The sponsor will provide the following investigational and control drugs, refe r to Table  6-1. 
Table 6-1 Investigational and control drug  
Investigational/ Control 
Drug  Pharmaceutical 
Dosage  Form  Route of 
Administration  Supply Type  Sponsor 
(global or local)  
Inclisiran sodium 300 mg 
(equivalent to 284 mg 
inclisiran*) in 1.5  mL Solution for 
injection  s.c. Solution for injection in prefilled syringe**  Global  
Matching s.c. placebo in 
1.5 mL  Solution for 
injection  s.c. Solution for injection 
in prefilled syringe**  Global  
Ezetimibe 10 mg  Capsule  p.o. Bottle  Global  
Matching p.o. placebo  Capsule  p.o. Bottle  Global  
*Inclisiran is also referred to as KJX839  
**The prefilled syringe (PFS) is a device component of the combination product, and it is regulated as part of 
the combination product in the context of this clinical trial. The PFS is not investigational, and no separate 
approval is required.  
6.1.2 Additional study treatments 
No other treatment beyond investigational drug and control drug is included in this trial.  
6.1.3 Treatment arms/group 
Participants will be randomized  at the baseline visit (Day 1) to one of the following three 
double- blind treatment groups in a 2:1:1 ratio:  
A) Inclisiran  sodium 300 mg s.c. and placebo p.o. (inclisiran arm) 
B) Placebo s.c. and ezetimibe 10 mg p.o. (ezetimibe arm) 
Novartis  Confidential  Page 34 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
C) Placebo s.c. and placebo p.o. (placebo arm) 
Each participant will receive one injection of blinded inclisiran or placebo on Day 1, and a 
secon d injection of blinded inclisiran or placebo on Day 90, unless there is a need for 
discontinuing inclisiran/placebo in the course of the study (refer to Section  3.3 and 
Section  9.1.1). Each participant will take blinded oral ezetimibe or placebo once daily on Day 
1 until the day before the Day 150 visit, unless there is a need for discontinuing oral 
ezetimibe/placebo in the course of the study.  
Subcutaneous injections of inclisiran sodium 300 mg and placebo will not be dispensed to the participants but rather administered by qualified, healthcare personnel at the study site on Day 1 and Day 90 of the study. Or al ezetimibe and placebo will be dispensed to the participants on 
Day 1, Day 30 and Day 90; and taken by the participant daily from Day 1 until the day before the Day  150 visit. Randomization will be stratified by screening LDL -C level (≤ 130 mg/dL 
versus > 130 mg/dL). 
6.1.4 Treatment duration 
The planned study treatment duration is 150 ±5 days . The EOS visit will be conducted 30 +5 
days after the Day 150 visit.  
Participants may be discontinued from the study treatment earlier due to safety reasons, at the 
discr etion of the investigator or the participant. They will continue to be followed up in the 
study until EOS as per Assessment Schedule ( Table  8-1).  
Depending on the availability of inclisiran in the investigator's country, the decision to switch a participant to a commercially available inclisiran product or to one of the locally available standard of care treatments after EOS will be left to the investigator's clinical judgment.  
6.2 Other treatment(s)  
6.2.1 Concomitant therapy 
Each concomitant drug must be individually assessed against all exclusion criteria/prohibited medication. If in doubt, the investigator should contact the  Novartis  medical monitor before 
randomizing a participant or allowing a new medi cation to be started. If the participant is 
already enrolled, contact  Novartis to determine if the participant should continue participation 
in the study. 
The investigator should instruct the participant to notify the study site about any new 
medications he/she takes after the participant is enrolled into the study. All medications, 
procedures, and significant non- drug therapies used by/performed on the participant within  
30 days prior to the first visit (Screening visit) must be documented in the appropri ate page of 
the eCRF.  
6.2.1.1 Permitted concomitant therapy requiring caution and/or action  
Investigators may prescribe concomitant medications or treatments deemed necessary to 
provide adequate supportive care except for those medications identified as “prohibite d” as 
listed in  Table  6-3. Specifically, participants should receive full supportive care during the study, 
Novartis  Confidential  Page 35 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
including treatment with antibiotics, antiemetics, antidiarrheals, analgesics, and oth er care as 
deemed appropriate, and in accordance with their institutional guidelines. 
Several medications and medication classes have been reported to affect the lipid profile. In 
order to accurately assess the effect of inclisiran as a monotherapy, it is desired to avoid any changes in lipids and lipoproteins induced by other medications. The medications listed in  
Table  6-2 are permitted if the doses of such medications are s table at least for 30 days prior to 
screening. The use of these medications by participants must remain unchanged from screening and throughout the trial. If the investigator suspects any drug to be lipid -change inducing but 
not listed in  Table  6-2, the investigator should contact the  Novartis  medical monitor before 
randomizing a participant.  
SARS -CoV- 2 (severe acute respiratory syndrome coronavirus 2, also referred to as COVID -19) 
vaccines are permitted among participants in this trial. There is no evidence to suggest that participants receiving either inclisiran/placebo or ezetimibe are at increased risk for AEs following a COVID -19 vaccination. However, since both inclisiran/placebo and COVID -19 
vaccines are administered s.c., it is recommended that the COVID -19 vaccine is administered 
+/- 7 days from s.c. inclisiran/placebo administration. Further, it is recommended that a different 
anatomical location is used for COVID -19 vaccine and s.c. inc lisiran/placebo to help 
differentiate potential local adverse reactions. COVID -19 vaccination administrations that 
occur either within 30 days prior to the first visit (Screening visit) and during the course of this study should be documented on the appropriate eCRF.  
Influenza vaccination, pneumococcal vaccination, or any other vaccines are also permitted among participants in this trial. Similar to the recommendations on COVID -19 vaccines, a  
7-day window between these vaccines and s.c. inclisiran/placebo administration and a different 
anatomical location are suggested.  
Table 6-2 Medication allowed under certain conditions 
Class of medication  Condition  
Anticoagulants  Stable dose for at least 30 days prior to screening and throughout the study  
Loop diuretics and thiazide 
diuretics  Stable dose for at least 30 days prior to screening and throughout the study  
Beta blockers  Stable dose for at least 30 days prior to screening and throughout the study  
Amiodarone  Stable dose for at least 30 days prior to screening and throughout the study  
Estrogens*  Stable dose for at least 30 days prior to screening and throughout the study  
Selective estrogen receptor 
modulators  Stable dose for at least 30 days prior to screening and throughout the study  
Androgens  Stable dose for at least 30 days prior to screening and throughout the study  
Anabolic steroids  Stable dose for at least 30 days prior to screening and throughout the study  
Anticonvulsants  Stable dose for at least 30 days prior to screening and throughout the study  
*Please note that as per Exclusion Criterion #14, female participants of child-bearing potential who are on oral 
contraception only (i.e. estrogens and progesterone) should be on stable dose for a minimum of 3 months prior 
to Day 1 and throughout the study.  
6.2.2 Prohibited medication 
Use of the treatments in  Table  6-3 is not allowed. This table is not considered all -inclusive. If 
in doubt, the investigator should contact the Novartis medical monitor before randomizing a 
Novartis  Confidential  Page 36 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
participant or allowing a new medication to be started. If the pa rticipant is already enrolled, 
contact Novartis to determine if the participant should continue his/her participation in the study.  
Table 6-3 Prohibited medication 
Class of medication  Prohibition 
period  Action taken  
LLT [statins, ezetimibe (other than control drug), bempedoic 
acid, psyllium preparations, fibrates, bile-acid sequestrants, red 
yeast rice, niacin >  200 mg/day, omega-3 fatty acids (DHA 
and/or EPA with a total dose >  1000 mg/day)], or any drug with 
unknown ingredients taken for the purpose of lipid-lowering, including over -the-counter or herbal therapies  
 At least 90 days 
prior to screening 
and until randomization  
 
Randomization 
and throughout the 
study  Do not randomize 
the participant  
 
Ask participants to 
stop taking LLTs.  
Contact Novartis 
for further 
guidance.  
Systemic cyclosporine and tacrolimus  
Systemic steroids 
Vitamin A derivatives or retinal derivatives for the treatment of 
dermatologic conditions (vitamin A in a multivitamin preparation 
is permitted)  
Antiviral therapies (protease inhibitors or direct acting antivirals)  At least 30 days 
prior to screening 
and until 
randomization  Do not randomize the participa nt 
 Randomization 
and throughout the 
study  Contact Novartis for 
further guidance.  
Investigational drugs  
Any RNAi -based therapeutics, including but not limited to siRNA 
or ASO Therapies  
 At least 30 days or 5 half -lives, 
whichever is longer, prior to 
screening and until 
randomization  Do not randomize the participant  
 Randomization 
and throughout the 
study  Discontinue study 
treatment  
Monoclonal antibodies directed towards PCSK9 such as evolocumab and alirocumab  At least  90 days 
prior to screening 
and until 
randomization  Do not randomize the participant  
Randomization and throughout the 
study  Discontinue study treatment  
6.3 Preparation and dispensation  
Each study site will be supplied with study drug in packaging as described under investigational 
and control drugs section. 
A unique medication number is printed on the study medication label. Site staff will identify the study medication kits to administer/dispense to the partic ipant by 
contacting the Interactive Response Technology (IRT) and obtaining the medication number(s). 
The study medication has a 2- part label (base plus tear -off label), immediately before 
administration/dispensing the medication kit to the participant, site personnel will detach the outer part of the label from the packaging and affix it to the source document. 
Novartis  Confidential  Page 37 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
For sites participating in the hybrid trial model with off- site visits by OHPs, where delivery of 
oral ezetimibe/placebo directly to a participant' s secure off -site location (e.g. home) is permitted 
by national and local governing regulations, then dispatch of oral ezetimibe/placebo directly to 
the participant may be performed under the accountability of the Investigator. Each shipment/provisioning w ill be for a maximum of 2 months'  supply. In this case, regular phone 
calls or virtual contacts will occur between the site and the participant for instructional purposes, safety monitoring, investigation of any adverse events, ensuring participants continue to benefit from treatment, and discussion of the participant's health status until the participants can resume visits at the study site.  
In addition, as per  Section  4.7, during a Public Hea lth emergency as declared by Local or 
Regional authorities i.e., pandemic, epidemic or natural disaster, that limits or prevents on- site 
study visits, delivery of study medication(s) directly to a participant's home may be permitted (if allowed by Local or  Regional Health Authorities and Ethics Committees as appropriate) in 
the event the investigator has decided that an on -site visit by the participant is no longer 
appropriate or possible, and that it is in the interest of the participant's health to administer the study treatment(s) even without performing an on -site visit. The dispatch of study medication(s) 
from the site to the participant’s home remains under the accountability of the investigator.  
6.3.1 Handling of study treatment and other treatment  
6.3.1.1 Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored safely and properly and kept in a secured location to which only the investigator and designated site personnel have access. Upon receipt, all  study treatment must be stored according to the 
instructions specified on the labels.  
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints are to be reported to the respective  Novartis Country Organization (CO) Quality Assurance.  
Medication labels will be in the local language and comply with the legal requirements of each country. They will include storage conditions for the study treatment but no information about the participant except for the medication numbe r. 
The investigator must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability log. Monitoring of drug accountability will be performed by field monitors during site or remote monitoring visits, and at the completion of the trial.  
If study treatment is administered at home (i.e., p.o. ezetimibe/placebo), participants will be asked to return all unused study treatment and packaging at the end of the study or at the time of discontinuation of study treatment.  
The site may destroy and document destruction of unused study treatment, drug labels and 
packaging as appropriate in compliance with site processes, monitoring processes, and per local regulation/guidelines. Otherwise, the investigator will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the  Novartis 
monitor or to the  Novartis address provided in the investigator folder at each site. 
Novartis  Confidential  Page 38 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
6.3.1.2 Handling of other treatment  
If a participant enters the stud y on medication that is known to be lipid change inducing (see 
Table  6-2), those medications should be specifically monitored. Changes (dose change or 
discontinuation) are not allowed during the study participation. 
6.3.2 Instruction for prescribing and taking study treatment  
Blinded s.c. injections of inclisiran/placebo, will not be dispensed to the participants, but will 
be administered by qualified healthcare personnel at the study site. 
The preferred site of injection is the abdomen. Alternative injection sites include the upper arm 
or thigh. Injections should not be made into areas of active skin disease or injury such as 
sunburns, skin rashes, inflammation, tattoos, or skin infections. 
Participants will be administered an injection of blinded s.c. inclisiran/placebo on Day 1 and 
Day 90, as specified in the Assessment Schedule ( Table  8-1) after all other study assessments 
have been completed for the visit.  
Blinded bottles containing 35 capsules of p.o. ezetimibe/placebo will be dispensed to the 
participants on Day 1 (1 bottle), Day 30 (2 bottles), and Day 90 (2 bottles) as assigned by the IRT. Participants should be instructed t o take the p.o. ezetimibe/placebo (1 capsule) at 
approximately the same time each day as follows: 
• Each dose may be taken with a glass of water with or without food. 
• Participants should be instructed to swallow whole capsules and not to chew or open them. 
• If vomiting occurs during the course of treatment, participants should not take the p.o. 
ezetimibe/placebo  again before the next scheduled dose. 
• Participants should be instructed not to make up missed doses. A missed dose is defined as when the full dose is not taken within 8 hours of the approximate time of the usual daily dosing. That day's dose should be skipped and the participant should continue treatment with the next scheduled dose. 
• On Day 1, Day 30, and Day 90, the dose should be taken after all asse ssments have been 
completed for the visit. The last dose of p.o. ezetimibe/placebo should be taken the day before the Day 150 visit. 
Table 6-4 Dose and treatment schedule  
Investigational / Control Drug (Name and 
Strength)  Dose  Frequency and/or Regimen  
Inclisiran sodium 300 mg  
(equivalent to 284  mg inclisiran*)  300 mg Day 1 and Day 90  
matching s.c. placebo  0 mg  Day 1 and Day 90  
Ezetimibe 10  mg 10 mg  once daily, Day 1 until day before Day 150 visit  
matching p.o. placebo  0 mg  once daily, Day 1 until day before Day 150 visit  
*also known as KJX839  
All kits of study treatment assigned by the IRT will be recorded in the IRT system.  All injections 
of inclisiran/placebo given to the participant as well as study drug interruptions/discontinuations (i.e., no injection at a designated dosing visit) during the study must be recorded on an appropriate eCRF and within IRT. All interruptions/discontinuations of p.o. ezetimibe/placebo 
Novartis  Confidential  Page 39 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
(i.e., doses not taken by the participant) during the study must be recorded on an appropriate 
eCRF; whereas bottles not dispensed to a participant must be recorded within IRT.  
6.4 Participant numbering, treatment assignment, randomization  
6.4.1 Participant numbering 
Each participant is identified in the study by a Participant Number (Participant No.), that is assigned when the participant is enrolled for screening and is retained for the participant throughout his/her parti cipation in the trial. A new Participant No. will be assigned at every 
subsequent enrollment if the participant is re -screened. The Participant No. consists of the 
Center Number (Center No.) (as assigned by Novartis to the investigative site) with a sequen tial 
participant number suffixed to it, so that each participant’s participation is numbered uniquely across the entire database. Upon signing the informed consent form, the participant is assigned to the next sequential Participant No. available. 
6.4.2 Treatment assignment, randomization  
At Visit 1 (Day 1), all eligible participants will be randomized via IRT to one of the treatment 
arms. The investigator or his/her delegate will contact the IRT after confirming that the participant fulfills all the inclusion/exclusion criteria. The IRT will assign a randomization number to the participant, which will be used to link the participant to a treatment arm and will specify a unique medication number for the first package of study treatment to be dispensed to the parti cipant.  
The randomization numbers will be generated using the following procedure to ensure that treatment assignment is unbiased and concealed from participants and investigator staff. A participant randomization list will be produced by the IRT provider using a validated system that automates the random assignment of participant numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication numbers. A separate medication lis t will be produced by or under the responsibility 
of Novartis Global Clinical Supply (GCS) using a validated system that automates the random assignment of medication numbers to packs containing the study treatment. 
Randomization will be stratified by  screening LDL- C results (≤ 130 mg/dL vs. > 130 mg/dL).  
The randomization scheme for participants will be reviewed and approved by a member of the 
Randomization Office.  
6.5 Treatment blinding  
Participants, investigator staff, persons performing the assessments, and  the Novartis trial team 
will remain blind to the identity of the treatment from the time of randomization until database lock. 
Unblinding a single participant at site for safety reasons (necessary for participant management) 
will occur via an emergency system in place at the site. As a result, the participant should be discontinued from the study treatment.  
The following methods will be used to maintain the blind: 
Novartis  Confidential  Page 40 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
(1) Randomization data will be kept strictly confidential until the time of final database lo ck. 
(2) The identity of the treatments will be concealed by the use of study treatment that are all 
identical in packaging, labeling, schedule of administration, appearance, taste, and odor. A double- dummy design is used because the identity of the study t reatment (inclisiran versus 
ezetimibe and matching placebos) cannot be disguised, as the drug products are visibly different.  
(3) Data with unblinding potential, such as lipid results and PCSK9 results collected after the randomization visit, will be kept blind until the time of final database lock. 
6.6 Dose escalation and dose modification  
6.6.1 Definitions of dose limiting toxicities (DLTs)  
DLTs are not applicable for the study. 
6.6.2 Dose modifications  
There are no dose adjustments or modifications of study treatment [i.e., study drug (s.c. 
inclisiran/placebo) or control drug (p.o. ezetimibe/placebo)]. For study treatment interruptions, 
discontinuations, and other follow -up requirements, please refer to  Section  10.1.1, 
Section  10.2.1, Table  16-2, and Table  16-3. 
6.6.3 Follow -up for toxicities 
All participants must be followed up for adverse events and serious adverse events for 30 days following the last doses of s.c. inclisiran/placebo or p.o. ezetimibe/p lacebo, whichever comes 
last. 
6.6.3.1 Follow -up on potential drug- induced liver injury (DILI) cases 
Participants with transaminase increase combined with total bilirubin increase may be indicative of potentially severe drug -induced liver injury (DILI), and should be considered as 
clinically important events and assessed appropriately to establish the diagnosis. The required clinical information, as detailed below, should be sought to obtain the medical diagnosis of the most likely cause of the observed laboratory a bnormalities.  
The threshold for potential DILI may depend on the participant’s baseline AST/ALT and total bilirubin value; participants meeting any of the following criteria will require further follow -up 
as outlined below: 
• For participants with normal ALT  and AST and total bilirubin value at baseline: AST or 
ALT > 3.0 x ULN combined with TBL > 1.5 x ULN 
• For participants with elevated AST or ALT or total bilirubin value at baseline: [AST or 
ALT > 2 x baseline] or [AST or ALT > 300 U/L] whichever occurs firs t, combined with 
[TBL > 2 x baseline, and > 2.0 x ULN] 
As DILI is essentially a diagnosis of exclusion, other causes of abnormal liver tests should be considered and their role clarified before DILI is assumed as the cause of liver injury.  
Novartis  Confidential  Page 41 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
A detailed histo ry, including relevant information such as review of ethanol consumption, 
concomitant medications, herbal remedies, supplement consumption, history of any pre -
existing liver conditions or risk factors, should be collected. 
Laboratory tests should include ALT, AST, TBL, direct and indirect bilirubin, gamma -glutamyl 
transferase (GGT), prothrombin time (PT)/International Normalized Ratio (INR), alkaline 
phosphatase (ALP), albumin, and creatine kinase (CK). If available, testing of Glutamate Dehydrogenase (GLDH) is additionally recommended. 
Perform relevant examinations (Ultrasound or Magnetic Resonance Imaging (MRI), 
Endoscopic retrograde cholangiopancreatography (ERCP)) as appropriate, to rule out an extrahepatic cause of cholestasis. Cholestasis (is defined as an ALP elevation > 2.0 x ULN with R value < 2 in participants without bone metastasis, or elevation of the liver- specific ALP 
isoenzyme in participants with bone metastasis).  
Note: The R value is calculated by dividing the ALT by the ALP, using multiples  of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury.  In clinical 
situations where it is suspected that ALP elevations are from an extrahepatic source, the GGT can be used if available. GGT may be less specific than ALP as a marker of cholestatic injury, since GGT can also be elevated by enzyme induction or by ethanol consumption. It is more sensitive than ALP for detecting  bile duct injury. 
Table  6-5 provides guidance on specific clinical and diagnostic assessments which can be 
performed to rule out possible alternative causes of observed liver function test (LF T) 
abnormalities.  
Table 6-5 Guidance on clinical and diagnostic assessments to rule out 
alternative causes of observed LFT abnormalities 
Disease  Assessment  
Hepatitis A (HAV), B (HBV), C (HCV), E (HEV) ● Immunoglobulin (Ig) M anti -HAV; hepatitis B virus surface antigen 
(HBsAg), IgM & IgG anti -hepatitis B core antigen (HBc), HBV 
deoxyribonucleic acid (DNA); anti -HCV, HCV ribonucleic acid (RNA), IgM 
& IgG anti -HEV, HEV RNA  
Cytomegalovirus (CMV), herpes 
simplex virus (HSV), Epstein -Barr 
virus (EBV) infection  ● IgM & IgG anti -CMV, IgM & IgG anti -HSV; IgM & IgG anti -EBV 
Autoimmune hepatitis  ● Antinuclear Antibodies (ANA) & Anti -Smooth Muscle Antibody (ASMA) 
titers, total IgM, IgG, IgE, IgA  
Alcoholic hepatitis  ● Ethanol history, GGT, mean corpuscular volume (MCV), carbohydrate-
deficient (CD) -transferrin  
Nonalcoholic steatohepatitis  ● Ultrasound or MRI  
Hypoxic/ischemic hepatopathy  ● Medical history: acute or chronic congestive heart failure, hypotension, 
hypoxia, hepatic venous occlusion. Ultrasound or MRI.  
Biliary tract disease  ● Ultrasound or MRI, ERCP as appropriate.  
Wilson disease (if <40 years old)  ● Caeruloplasmin  
Hemochromatosis  ● Ferritin, transferrin  
Alpha -1-antitrypsin deficiency  ● Alpha -1-antitrypsin  
Other causes should also be considered based upon participants’ medical history 
(hyperthyroidism / thyrotoxic hepatitis – triiodothyronine (T3), thyroxine (T4), TSH; 
Novartis  Confidential  Page 42 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
cardiovascular disease (CV) / ischemic hepatitis – electrocardiogram (ECG), prior hypotensive 
episodes; Type 1 diabetes / glycogenic hepatitis). 
Following appropriate causality assessments, as outlined above, the causality of the treatment 
is estimated as “probable” (i.e., > 50% likely) if it appears greater than all other possible causes of liver injury combined. The term “treatment -induced” indicates probably caused  by the 
treatment, not by something else, and only such a case can be considered a DILI case and should be reported as an SAE.  
All cases confirmed on repeat testing meeting the laboratory criteria defined above, with no other alternative cause for LFT abnormalities identified, should be considered as “medically significant,” and thus, meet the definition of SAE and should be reported as SAE using the term “potential treatment -induced liver injury.” All events should be followed up with the outcome 
clearly documented. 
Please also refer to  Section  16.2 for liver event and laboratory trigger definitions & follow -up 
requirements.  
6.7 Additional treatment guidance  
6.7.1 Treatment compliance 
The investigator must promote compliance of the p.o.  study treatment (ezetimibe/placebo) by 
instructing the participant to take it exactly as prescribed and by stating that compliance is 
necessary for the participant’s safety and the validity of the study. The participant must also be instructed to contact the investigator if he/she is unable for any reason to take the study 
treatment as prescribed. Compliance will be assessed by the investigator and/or study personnel at each visit using pill counts and information provided by the participant. This informat ion 
should be captured in the source document and the appropriate eCRF at each visit. All study 
treatment dispensed and returned must be recorded in the Drug Accountability Log. 
Blinded investigational s.c. injections (inclisiran/placebo) will be administered at the study site. 
This information must be captured in the source document, the appropriate eCRF and in the Drug Accountability Log. 
6.7.2 Recommended treatment of adverse events 
AEs should be treated according to local practice and guidelines, and is at the discretion of the 
investigator and treating physician.  
For participants with injection site reaction, antihistamines, local or systemic steroids can be 
used at the investigator’s discretion depending on the severity of the reaction. 
Medication used to tr eat AEs must be recorded on the appropriate eCRF.  
6.7.3 Emergency breaking of assigned treatment code 
Emergency code breaks must only be undertaken when it is required to in order to treat the 
participant safely.  
Most often, discontinuation from study treatment and knowledge of the possible treatment assignments are sufficient to treat a study participant who presents with an emergency condition. 
Novartis  Confidential  Page 43 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Emergency treatment code breaks are performed using the IRT. When the investigator contacts 
the system to break a treatment code for a participant, he/she must provide the requested participant identifying information and confirm the necessity to break the treatment code for the participant. The investigator will then receive details of the investigational drug treatment for the specified participant and a fax or email confirming this information. The system will automatically inform the Novartis  monitor for the site and the study team that the code has been 
broken. 
It is the investigator’s responsibility to ensure that th ere is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency. The investigator 
will provide: 
• protocol number 
• name 
• participant number  
In addition, oral and written information to the participant must be provided on how to contact 
his/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at any time.  
After an emergency unblinding, study treatment should be permanently discontinued. The participant will continue to be followed up  in the study unless informed consent is withdrawn 
(Section  9.1.1 and Section  9.1.2) or until participant completed the EOS  visit as per Assessment 
Schedule ( Table  8-1). 
7 Informed consent procedures  
Eligible participants may only be included in the study after providing (witnessed, where required by law or regulation) Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent. 
If applicable, in cases where the participant's representative(s) gives consent (if allowed 
according to local requirements), the participant must be informed about the study to the extent possible given his/her level of understanding. If the participant is capable of doing so, he/she must indicate agreement by personally signing and dating the written informed cons ent 
document. 
Informed consent must be obtained before conducting any study- specific procedures (e.g., all 
of the procedures described in the protocol). The process of obtaining informed consent must 
be documented in the participant source documents. 
Novar tis will provide to investigators in a separate document a proposed informed consent form 
that complies with the (ICH  E6 Guideline  2017 ) guidelines and regulatory requirements and is 
considered appropriate for this study. Any changes to the proposed consent form suggested by 
the investigator must be agreed by Novartis before submission to the IRB/IEC.  
Information about common side effects already known about the investigational treatment (inclisiran) can be found in the IB and information about common side effects known about the other study treatment (ezetimibe) can be found in the local package insert. This information will be included in the participant informed consent and should be di scussed with the participant 
Novartis  Confidential  Page 44 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
during the study as needed. Any new information regarding the safety profile of the 
investigational drug that is identified between IB updates will be communicated as appropriate, for example, via an investigator notification ( IN) or an aggregate safety finding. New 
information might require an update to the informed consent and then must be discussed with the participant.  
The following informed consents are included in this study: 
• Main study consent  
• Optional Consent for Additional Research to allow future research on data/samples 
collected during this study  
• As applicable, Informed Consent for Off- site Visits/Procedures to allow for off -site 
visits/procedures as described in  Section  3.1 
• As applicable, Pregnancy Outcomes Reporting Consent for female participants who took study treatment 
Women of child bearing potential must be informed that taking the study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate in the study they must adhere to the contraception requirements. 
A copy of the approved version of all consent forms must be provided to Novartis  after IRB/IEC 
approval. Participants will be asked to complete an optional questionnaire to provide feedback on their 
clinical trial experience.  
As per  Section  4.7, during a Public Health emergency as declared by Local or Regional 
authorities i.e. pandemic, epidemic or natural disaster, that may challenge the ability to obtain a standard written informed consent due to limits that prevent an on -site visit, Investigator may 
conduct the informed consent discussion remotely (e.g., telephone, videoconference) if allowable by a local Health Authority.  
Guidance issued by local regulatory bodies on this aspect prevail and must be implemented and appropriately documented (e.g., the presence of an impartial wi tness, sign/dating separate ICFs 
by trial participant and person obtaining informed consent, etc.). 
8 Visit schedule and assessments 
The Assessment Schedule ( Table  8-1) lists when all study assessments are performed. All data 
obtained from these assessments must be supported in the participant’s source documentation. The “X” in the table denotes the assessments to be recorded in the clinical database or received electronically from a vendor. The "S " in the table denotes the assessments that are only in the 
participant's source documentation and do not need to be recorded in the clinical database. 
Participants should be seen for all visits/assessments as outlined in the Assessment Schedule 
(Table  8-1) During the double- blind treatment period, a window of +/ - 5 days based on the Day 
1 randomization date is acceptable for Visit 2 (Day 30), Visit 3 (Day 90), and Visit 4 (Day 150). Visit 5 (Da y 180 or EOS) will be 30 days after Day 150 visit, with an acceptable window of up 
to + 5 days. Missed or rescheduled visits should not lead to automatic discontinuation. 
Novartis  Confidential  Page 45 of 84 
Amended Protocol Version  01 (Clean ) Protocol No. CKJX839D12304  
 
Participants who prematurely discontinue from study treatment are to continue with pl anned 
study visits and be retained until Day 180 as indicated in the Assessment Schedule.  
Participants who discontinue from study or withdraw their consent/oppose the use of their 
data/biological samples should be scheduled for a final evaluation visit if they agree, as soon as 
possible, at which time all of the assessments listed for the final visit will be performed. At this final visit, all dispensed investigational product should be reconciled, and the adverse event and concomitant medications not previously reported must be recorded on the eCRF. 
Participants will have to comply with the following restrictions during the study:  
• Fasted for at least 10 hours for all visits to obtain fasting lipids and/or glucose blood 
samples. If the participant is not fas ting at the time of Informed Consent signature, he/she 
will have to return for a blood draw in a fasting state. 
• Must refrain from unaccustomed strenuous physical activity for 48 hours prior to any study visit. 
As per  Section  4.7, during a Public Health emergency as declared by Local or Regional 
authorities (i.e., pandemic, epidemic or natural disaster) that limits or prevents on -site study 
visits, alternative methods of providing continuing care may be implemented by the investigator as the situation dictates. If allowable by a local Health Authority and depending on operational capabilities, phone calls, virtual contacts (e.g., tele consult) or visits by site staff/ home nursing staff to the participant´s home, can replace on -site study visits, for the duration of the disruption 
until it is safe for the participant to visit the site again.  
Novartis  Confidential  Page 46 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Table 8-1 Assessment Schedule 
Period  Screening  Baseline  Double -Blind Treatment Period4 Safety Follow -up 
Visit Name  Screening1 V1  V21 V3 V4 2 V5 (EOS)3,4 
Days  -14 to -1 1 30  90 150 180 +5  
Informed consent  X           
Inclusion / 
Exclusion criteria  X X         
Demography  X           
Smoking and 
alcohol history  X           
Medical 
history/current 
medical 
conditions  X           
Prior or 
concomitant 
medication5 X X X X X X 
Surgical/medical 
procedures5 X X X X X X 
Physical 
Examination  S S   S  S 
Body 
Height/Weight  X           
Vital Signs6 X X X X X X 
AEs/SAEs  X X X X X X 
Lifestyle 
instructions    S S S S S 
Electrocardiogram 
(ECG)    X         
Follicle stimulating 
hormone (FSH)  X7           
Novartis  Confidential  Page 47 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Period  Screening  Baseline  Double -Blind Treatment Period4 Safety Follow -up 
Visit Name  Screening1 V1  V21 V3 V4 2 V5 (EOS)3,4 
Days  -14 to -1 1 30  90 150 180 +5  
Pregnancy Test 
(serum)8 X           
Pregnancy Test 
(urine)9   X X X X X 
Thyroid 
stimulating 
hormone10 X              
Fasting Lipid 
Profile11 X X X X X   
Fasting Lp(a)12   X     X   
PCSK913   X X X X   
Clinical 
Chemistry10 X           
Limited 
Chemistry10   X X   X X 
Hematology10  X       X 
HbA1c10  X     X 
Urinalysis14 X         X 
Coagulation 
Panel10   X         
Enter participant 
visit in IRT  X X X X X X 
Randomization    X         
Study drug administration - 
s.c. 
inclisiran/placebo    
X15   
X15     
Dispense 
ezetimibe/placebo    S S S     
Novartis  Confidential  Page 48 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Period  Screening  Baseline  Double -Blind Treatment Period4 Safety Follow -up 
Visit Name  Screening1 V1  V21 V3 V4 2 V5 (EOS)3,4 
Days  -14 to -1 1 30  90 150 180 +5  
Control drug 
administration - 
p.o. 
ezetimibe/placebo       
X16 X16 X16 X16   
Ezetimibe/placebo 
compliance      X16 X16 X16   
Disposition  form X       X17 X 
X Assessment to be recorded in the clinical database or received electronically from a vendor  
1 Visit may be performed off -site in certain countries and sites as determined by protocol needs and based on national and local/site regulations.  
2 Visit 4 is also the EOT visit if the participant completes the study treatment as per protocol.  
3 Visit may be performed off -site in certain countries and sites as determined by protocol needs and based on national and local/site regulations 
or over the telephone if an on- site visit is not possible.  During a telephone call, only AEs/SAEs and concomitant medications will be followed.  
4 When study treatment is discontinued early,  participants should continue with all of  their planned study visits and be retained until Day 180. A 
window of +/ - 5 days based on the Day 1 visit date is acceptable for Visit 2 (Day 30), Visit 3 (Day 90), and Visit 4 (Day 150).  
5 All medications, procedures, and significant non-drug therapies used by/performed on the participant within 30 days prior to the first visit (Screening visit) and throughout the study must be documented in the appropriate page of the eCRF.  
6 Blood pressure and pulse will be taken 3 times in sitting position.  
7 Required for any female participant who is considered as surgically sterile or post -menopausal in the absence of medical documentation 
confirming this reproductive/menopausal status at screening (see 
Section 8.4.3). 
8 Only in women of childbearing potential (see Section 5.2 - Exclusion Criterion #14 and Section 8.4.3). Serum samples will be sent to the 
central lab for analysis.   
9 Only in women of childbearing potential (see Section 5.2- Exclusion Cri terion #14 and Section 8.4.3). Performed locally, using central 
laboratory kit supplies.  If urine test is positive, a serum sample will be sent to the central lab for analysis.  
10 Performed by the central lab.  See Table 8-3 . 
11 Performed by the central lab. Includes LDL-C, Apo A -1, Apo B, Apo B/Apo A -1 ratio, non- HDL-C, TC, HDL-C, TC/HDL-C ratio, triglycerides.  
12 Performed by the central lab.  
13 Performed by the central lab.  An additional aliquot will be made from the PCSK9 sample in order to allow analysis of proteins related to 
dyslipidemia or study drug mechanism.  
14 Performed locally, using central laboratory kit supplies. If  Macroscopic Panel (Dipstick) results are positive (abnormal) for Leukocyte 
Esterase, Nitrite, Blood, and/or Protein, then a urine sample will be sent to central lab to perform a Macroscopic Panel and a Microscopic 
Reflexive Panel  if positive for Leukocyte Esterase, Nitrite, Blood, Protein. Refer to Table 8-3 . 
15 Subcutaneous inclisiran/placebo will be administered by qualified healthcare personnel after all other study assessments have been 
completed for this visit.  
Novartis  Confidential  Page 49 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Period  Screening  Baseline  Double -Blind Treatment Period4 Safety Follow -up 
Visit Name  Screening1 V1  V21 V3 V4 2 V5 (EOS)3,4 
Days  -14 to -1 1 30  90 150 180 +5  
16 Participant to take one capsule ezetimibe/placebo a day starting from Day 1 until the day before the Day 150 visit (see Section 6.3.2 ). 
Compli ance will be checked until the visit following the last dose of ezetimibe/placebo.  
17 End of Treatment disposition form should be completed prior to Day 150 if the participant discontinue s study treatment prior to Day 150.  
Novartis  Confidential  Page 50 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
8.1 Screening  
Screening  
Screening activities must be initiated only after the ICF has been signed. 
If a safety laboratory assessment during the screening period  is outside of the range specified 
in the exclusion criteria, the assessment may be repeated one time prior to randomization. If the 
repeat value remains outside of the specified ranges, the participant will be considered a screen fail and must be excluded from the study. 
It is generally not permissible to re -screen a participant if he/she fails the initial screening. Re -
screening is allowed  once, if a participant has an initiation, a dose  change or a discontinuation 
of medications that are known to induce lipid and lipoprotein changes (see  Section  5.2 - 
Exclusion Criterion #3) within 30 days prior to screening or post screenin g but before 
randomization. Participants may be re -screened after being on a stable dose for 30 days or after 
treatment discontinuation of such medications for 30 days. Re-screened participants must provide new written informed consent.  A new participant 
number will be assigned to the re -screened participants and the site must record the re -screening 
information in the corresponding eCRF and in IRT. All screening procedures will need to be 
re-performed. 
8.1.1 Information to be collected on screening failures  
Participants who sign the ICF and are subsequently found to be ineligible at time of 
randomization will be considered a screen failure. The reason for screen failure should be 
recorded on the appropriate eCRF page. The demographic information, informed consent, and inclusion/exclusion eCRF pages must be completed for screen failure participants. No other data are required to be entered into the clinical database for participants who are screen failures, unless the participant experienced a SAE during the screen ing period (see Section  10.1.3 for 
reporting details). If the participant fails to be randomized, the IRT must be notified within  
2 days of the screen fail.  
Participants who are randomized  and fail to start treatment (e.g., participants randomized in 
error) will be considered an early terminator. The reason for early termination should be recorded in the appropriate eCRF page. 
8.2 Participant demographics/other baseline characteristics  
Country- specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with the eCRF.  
Participant demographic and baseline characteristics collected on all participants include: age, sex, race, ethnici ty, vital signs, height, weight, smoking/alcohol history, medical history/current 
medical conditions present before signing the ICF(where possible, diagnoses and not symptoms should be recorded), and relevant laboratory tests. 
Novartis  Confidential  Page 51 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Participant race/ethnicity da ta are collected and analyzed to identify any differences in safety 
and/or efficacy due to these factors, as well as to assess the diversity of the study population as 
required by Health Authorities. 
All prescription and over- the-counter medications, proce dures, and significant non- drug 
therapies, used by/performed on the participant within 30 days prior to the first visit (Screening 
visit) and throughout the study must be documented in the appropriate page of the eCRF (see  
Section  6.2.1).  
Investigators will have the discretion to record abnormal test findings on the medical history eCRF whenever, in their judgment, the test abnormality occurred prior to the informed consent signature.  
8.3 Efficacy  
All efficacy assessments are biomarkers which will be analyzed at a central laboratory. Specimens for efficacy assessments will be collected at time points specified in the Assessment Schedule ( Table 8-1 ). Participants must be in a fasted state for all of these laboratory 
assessments. Details regarding the collection, processing, shipping and storage of the samples for central laboratory will be provided in a Lab oratory Manual. 
Starting from the time of the  randomization visit (Day 1), the results from all lipid parameter 
measurements must be blinded to participants, investigator staff, persons performing the assessments, the monitors, and the Novartis Clinical Tr ial Team (CTT) until database lock.  
8.3.1 LDL-C 
The primary efficacy assessment will be LDL -C, as tested and reported by the central laboratory 
as part of the Lipid Panel at the frequency shown in Table  8-1. Participants must be fasting for 
all LDL -C assessments.  
8.3.2 Additional efficacy assessments 
Additional efficacy assessments will include non -HDL -C, HDL -C, TC, TC/HDL -C ratio, Apo 
A-1, Apo B, Apo B/Apo A -1 ratio, Lipoprotein A (Lp(a), and PCSK9. Lipid parameters, Lp(a) 
and PCSK9 will be tested and reported by the central laboratory at the frequency shown in Table  8-1. Participants must be fasting for all lipid and lipoprotein testing.  
8.3.3 Appropr iateness of efficacy assessments  
Inclisiran is a siRNA which acts to  inhibit the synthesis of PCSK9 protein, which consequently 
reduces LDL -C in circulation. LDL -C is a well -defined and validated laboratory parameter and 
is routinely assessed in clinical t rials. LDL -C reduction is an accepted surrogate for CV risk 
reduction, e.g., for statins and PCSK9- blocking monoclonal antibodies. While multiple factors 
contributing to the development of ASCVD have been described, strong and consistent evidence from genetics, epidemiology, Mendelian randomization studies, and randomized trials have established that LDL -C is not only a laboratory parameter of increased risk, but also a 
causal and modifiable factor in ASCVD  (Mach  et al 2020 ). Laboratory tests related to the 
primary and secondary endpoints are in line with the expected efficacy of inclisiran. 
Novartis  Confidential  Page 52 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
8.4 Safety  
Safety assessments are specified below, with the Assessment Schedule ( Table  8-1) detailing 
when each assessment is performed.  
For details on AE collection and reporting, refer to AE section (Section  10.1).  
As per Section  4.7, during a Public Health emergency as declared by Local or Regional 
authorities i.e. pandemic, epidemic or natural disaster, that limit s or prevents on- site study visits, 
regular phone or virtual calls can occur (every 4 weeks or more frequently if needed) for safety 
monitoring and discussion of the participant´s health status until it is safe for the participant to visit the site again.  
Table 8-2 Safety assessments 
Assessment  Specification  
Physical 
examination  A complete physical examination will include the examination of general appearance, 
skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, 
lymph nodes, extremities, vascular, and neurological. If indicated based on medical 
history and/or symptoms, rectal, external genitalia, breast, and pelvic exams will be 
performed. 
Information for all physical examinations must be included in the source documentation at 
the study site. Clinically relevant findings that are present prior to signing informed 
consent must be recorded on the appropriate eCRF that captures medical h istory. 
Significant findings made after signing informed consent which meet the definition of an 
AE must be recorded as an AE.  
Vital signs  Vital signs include blood pressure (BP) and pulse measurements. After the participant has 
been sitting for five minutes, with back supported and both feet placed on the floor, systolic and diastolic blood pressure and pulse will be measured three times using an 
automated validated device with an appropriately sized cuff. The repeat sitting 
measurements will be made at 1 - 2 minute intervals and the mean of the three 
measurements will be used. In case the cuff sizes available are not large enough for the participant's arm circumference, a sphygmomanometer with an appropriately sized cuff 
may be used.  
Height and weight  Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram (kg) in indoor 
clothing, but without shoes) will be measured.  
8.4.1 Laboratory evaluations  
Specimens will be obtained at the time points detailed in the Assessment Schedule ( Table  8-1). 
Details on what is included in chemistry (full and limited panels), hematology, coagulation, 
thyroid stimulating hormone, and urinalysis laboratory evaluations as well as pregnancy testing and FSH are provided in Table  8-3. 
The central laboratory will flag laboratory values falling outside of the normal ranges on the central laboratory reports. Investigators are responsible for reviewing these abnormal values for clinical significance, signing the laboratory reports to indicate their review, and reporting values considered clinically significant in the appropriate eCRF. Any clinically significant abnormal laboratory value should be evaluated and followed- up by the investigator until normal or a cause 
for the abnormality is determined. Clinically significant abnormalities must be recorded as either medical history/current medical conditions or AEs as appropriate.  
In addition to  Table  8-3, see Section  6.6.3.1 for follow -up on potential DILI  cases,  
Section  10.2.1 for liver safety monitoring, and  Section  16.2 for specific liver event and 
Novartis  Confidential  Page 53 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
laboratory test trigger definitions and follow -up requirements and  Section  10.2.2  for renal 
safety monitoring.  
Central laboratory will be used for analysis of all specimens collected, with the exception of 
urine pregnancy tests  and manual dipstick urinalysis , which will b e done locally (using testing 
materials supplied by the central laboratory). Serum pregnancy tests at screening will be done by the central laboratory. Details on the collections, shipment of samples and reporting of results by the central laboratory are p rovided to investigators in a Laboratory Manual. 
As per  Section  4.7, during a Public Health emergency as declared by Local or Regional 
authorities, i.e. pandemic, epidemic or natural disaster, that limits or prevents on -site study visits, 
if participants cannot visit the site for protoco l specified safety lab assessments, an alternative 
lab (local) collection site may be used. 
Table 8-3 Safety Laboratory Assessments 
Test Category  Test Name  
Hematology  Hematocrit, Hemoglobin, Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular 
Hemoglobin Concentration (MCHC), MCV, Platelets,  Erythrocytes, Leukocytes, 
Differential (% of Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils)  
HbA1c  HbA1c  
Chemistry (full 
panel)  AST, ALT, ALP, GGT, TBL, Direct Bilirubin, Indirect Bilirubin, Albumin, Creatinine, 
eGFR, Blood Urea Nitrogen (BUN), Uric Acid, Fasting Plasma Glucose (FPG), CK, 
Calcium, Magnesium, Phosphate, Chloride, Sodium, Potassium  
Chem istry 
(limited panel)  AST, ALT, ALP, GGT, TBL, Creatinine, eGFR, FPG, CK  
Urinalysis  Macroscopic Panel (Dipstick): Color, Bilirubin, Occult Blood, Macroscopic Blood, Glucose, Ketones, Leukocyte esterase, Nitrite, pH, Protein, Specific Gravity, Urobilinogen.  
If dipstick results are positive (abnormal)  for Leukocyte Esterase, Nitrite, Blood, and/or 
Protein, then a urine sample will be sent to the central lab to perform a Macroscopic 
Panel  and a Microscopic Reflexive Panel if there are positive results for Leukocyte 
Esterase, Nitrite, Blood, and/or Protein.  
Microscopic Panel: Erythrocytes, Leukocytes, Casts, Crystals, Bacteria, Epithelial cells.  
Coagulation  PT, INR, Activated partial thromboplastin time (APTT)  
Thyroi d Function  Thyroid Stimulating Hormone  
Pregnancy Test  Serum and Urine Pregnancy (see Section 8.4.3 ) 
A confirmatory serum pregnancy test is required in case of a positive urine pregnancy 
test. 
Follicle Stimulating 
Hormone  FSH (see  Section 8.4.3
) 
Required for any female participant considered surgically sterile or post -menopausal in 
the absence of medical documentation confirming this reproductive/menopausal status 
at screening.  
Liver Event 
Testing and Liver 
Follow -up Testing  Albumin, ALP, ALT, AST, CK, GGT, GLDH, INR, PT, and Total Bilirubin (TBL). Test for 
hemolysis (haptoglobin, reticulocytes, unconjugated [indirect] bilirubin).  
These tests are in addition to routine testing, to be performed only in follow -up to safety 
events when indicated in  Section  6.6.3.1 , Section  10.2.1  and Section  16.2. 
Renal Follow -up Urine protein for Protein:Creatinine ratio (PCR),  Serum Creatinine.  
Repeat standard urinalysis.  
Macroscopic Panel (Dipstick) Color, Bilirubin, Occult Blood, Macroscopic Blood, Glucose, Ketones, Leukocyte esterase, Nitrite, pH, Protein, Specific Gravity, 
Urobilinogen.  
If dipstick results are positive (abnormal), for Leukecyte Esterase, Nitrite, Blood and/or Protein, then a urine sample will be sent to the central lab to perform a Macroscopic  
Macroscopic Panel  and a Microscopic Reflexive Panel if there are positive results for 
Novartis  Confidential  Page 54 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Test Category  Test Name  
Leukocyte Esterase, Nitrite, Blood, and/or Protein.  
Microscopic Panel: Erythrocytes, Leukocytes, Casts, Crystals, Bacteria, Epithelial cells.  
These tests are in addition to routine testing, to be performed only in follow -up to safety 
events when indicated in  Section  10.2.2 . 
8.4.2 Electrocardiogram (ECG)  
Single 12 lead ECGs will be conducted using local ECG machines. ECGs must be recorded 
after 10 minutes rest in the supine position to ensure a stable baseline.  The preferred sequence 
of cardiovascular data collection during study visits is ECG collection first, followed by vital 
signs, and blood sampling. 
ECGs will be locally collected and evaluated. Interpretation of the baseline tracing must be 
made by a qualified physician and documented on the ECG CRF. Each ECG tracing should be 
labeled with the study number, participant initials (where regulations permit), participant number, date, and kept in the source documents at the study site. 
 The QT interval corrected by Fridericia's formula (QTcF) should be used for clinical decisions.  
The investigator must calculate QTcF if it is not auto -calculated by the ECG machine. Clinically 
significant abnormalities at baseline should be reported on the adverse events eCRF.  
Clinically significant findin gs must be discussed with Novartis prior to enrolling the participant 
in the study. Additional, unscheduled, safety ECGs may be repeated at the discretion of the investigator at 
any time during the study as clinically indicated. For any ECGs with participant safety concerns, two additional ECGs must be performed to confirm the safety finding. ECG safety monitoring, or a review process, should be in place for clinically significant ECG findings at baseline before administration of study treatment and during the study.  
New or worsened clinically significant findings occurring after informed consent must be recorded as adverse events.  The original ECGs  on non- heat-sensitive paper and  a certified copy 
on non- heat sensitive paper, appropriately signed, must be co llected and archived at the study 
site. 
8.4.3 Pregnancy and assessments of fertility  
All pre -menopausal women who are not surgically sterile will have a serum pregnancy test 
performed at the screening visit, and urine pregnancy tests at all other study visits. I f a urine 
pregnancy test is positive, then a serum pregnancy test will be performed. 
Additional pregnancy testing might be performed if requested by local requirements.  
If participants cannot visit the site to have serum pregnancy tests during a Public Hea lth 
emergency as declared by Local or Regional authorities , i.e., pandemic, epidemic or natural 
disaster, that limits or prevents on -site study visits, urine pregnancy test kits may be used. 
Relevant participants can perform the urine pregnancy test at home and report the result to the 
site. It is important that participants are instructed to perform the urine pregnancy test first and only if the test result is negative proceed with the administration of the study treatment. A communication process should be established with the participant so that the Site is informed and can verify the pregnancy test results (e.g., following country specific measures). 
Novartis  Confidential  Page 56 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
9 Discontinuation and completion  
9.1 Discontinuation from study treatment and from study  
9.1.1 Discontinuation from study treatment  
Discontinuation of study treatment for a participant occurs when study treatment is permanently 
stopped for any reason (prior to the planned completion of study drug or control drug administration, if a ny) and can be initiated by either the participant or the investigator. If the 
participant permanently discontinues p.o. ezetimibe/placebo or s.c.  inclisiran/placebo, then the 
participant’s entire  study treatment must be stopped. The treatment disposition CRF will be 
completed to reflect that the participant has permanently discontinued study  treatment  (both p.o. 
study drug and s.c. study drug).  
The investigator must discontinue study treatment for a given participant if he/she believes that 
continuation would negatively impact the participant's well -being.  
Discontinuation from study treatment is required under the following circumstances:  
• Participant/guardian decision  
• Pregnancy 
• Use of prohibited treatment as per recommendations in the prohibited medication  
Section  6.2.2  
• Any situation in which continued study participation might result in a safety risk to the participant  
• Severe and persistent (>  14 days despite appropriate trea tment) reactions at the injection 
site and any type of anaphylactic reactions  
• Intolerable adverse events 
• Unexplained increases in transaminases (ALT or AST) or total bilirubin confirmed by repeat 
test as follows:  
• ALT or AST >  8 x ULN 
• ALT or AST >  5 x ULN for more than 2 weeks 
• ALT or AST >  3 x ULN with simultaneous or subsequent elevation of total 
bilirubin > 2 x ULN  
• ALT or AST >  3 x ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>  5%) 
The investigator should evaluate to see if other causes for the laboratory abnormalities are 
immediately apparent, such as obstructive gall bladder or bile duct disease, viral or alcoholic hepatitis, malignancy involving the liver, congestive hepatopathy, other hepatotoxins or heritable disorders. Please also refer to  Section 16.2 Appendix 2. 
• Unexplained CK > 10 x ULN confirmed by repeat test when the CK elevation is 
associated with muscle pain, muscle tenderness and/or muscle weakness, or new onset renal dysfunction with no other alternative explanation  
• Following emergency unblinding 
Novartis  Confidential  Page 57 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
• Any other laboratory abnormalities that in the judgment of the investigator, taking into 
consideration the participant's overall status, prevents the participant from continuing 
participation in the study  
If discontinuation from study treatment occurs, the investigator should make a reasonable effort to understand the primary reason for the participant’s discontinuation from study treatment and record this information.  
Participants who discontinue from study treatment should continue with planned study visits and be  retained until Day 180 as indicated in the Assessment Schedule.  Refer to Table 8 -1 
Assessment Schedule.  
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain 
regular telephone contact with the participant, or with a person pre -designated by the participant. 
This telephone contact should preferably be done according to the study visit schedule. After discontinuation from study treatment, at a minimum, i n abbreviated visits, the following 
data should be collected at clinic visits or via telephone/email contact:  
• New / concomitant treatments  
• AEs / SAEs  
The investigator must also contact the IRT to register the participant’s discontinuation from 
study treatment. 
If discontinuation occurs because treatment code has been broken, please refer to Emergency 
breaking of treatment code section.  
9.1.2 Discontinuation from study 
Discontinuation from study is when the participant permanently stops receiving the study treatme nt, and further protocol- required assessments or follow -up, for any reason. 
If the participant agrees, a final evaluation at the time of the participant’s study discontinuation should be made as detailed in the assessment table (refer to Section  8). 
9.1.3 Lost to follow -up 
For participants whose status is unclear because they fail to appear for study visits or fail to respond to any site attempts to contact them without stating an intention to discontinue from study treatment or discontinue from study or withdraw consent (or exercise other participant's data privacy rights), the Investigator must show "due diligence" by documenting in the source documents steps taken to contact the participant, e.g. dates of telephone calls, registered letters, etc. A participant should not be considered as lost to follow -up until due diligence has been 
completed or until the end of the study. 
9.2 Withdrawal of informed consent/Opposition to use 
data/biological sampl es 
Withdrawal of consent/opposition to use data/biological samples occurs in countries where the 
legal justification to collect and process the data is consent and when a participant:  
• Explicitly requests to stop use of their data , and 
Novartis  Confidential  Page 58 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
• No longer wishes to receive study treatment, and  
• Does not want any further visits or assessments (including further study- related contacts)  
This request should be as per local regulations (e.g., in writing) and recorded in the source 
documentation. 
Withdrawal of consent impacts ability to further contact the participant, collect follow -up data 
(e.g. to respond to data queries) and potentially other country- specific restrictions. It is therefore 
very important to ensure accurate recording of withdrawal vs. discontinuation based on the 
protocol definition of these terms.  
In this situation, the investigator should make a reasonable effort (e.g., telephone, e -mail, letter) 
to understand the primary reason for the participant’s decision to withdraw their consent 
exercise data privacy rights and record this information. The Investigator shall clearly document if the participant has withdrawn his/her consent for the use of data in addition to a study discontinuation. 
Study treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.  
Further attempts to contact the participant are not allowed unless safety findings require communicating or follow -up. 
If the participant agrees, a final evaluation at the time of the participant’s withdrawal of consent/exercise data privacy rights should be made as detailed in the assessment table (refer to Section  8). 
Further details on withdrawal of consent or the exercise of participant's data privacy rights are included in the corresponding informed consent form. 
9.3 Study completion and post -study treatment  
The end of the study is defined as the date of the last visit of the last participant in the study or last scheduled procedure or follow -up shown in Table  8-1 Visit Evaluation Schedule for the last 
participant in the study globally. 
Study completion is defined as when the last participant finishes their last study visit and any 
repeat assessments associated with this visit have been documented and followed -up 
appropriately by the investigator or, in the event of an early study termination decision, the date of that decision (e.g., each participant will be required to complete the study in its entirety and, thereafter, no further study treatment will be made available to them).  
All randomized and/or treated participants should have a safety follow-up call or the EOS visit conducted at least 30 days after  the Day 150 visit . The information collected is entered on the 
EOS eCRFs and/or kept as source documentation, as applicable. All SAEs reported during this time period must be reported as described in Section  10.1.3. Documentation of attempts to 
contact the participant should be recorded in the source documentation. 
Depending on the availability of inclisiran in the investigator's country, the decision to swi tch 
a participant to a commercially available inclisiran product or to one of the locally available 
standard of care treatments  after EOS  will be left to the investigator's clinical judgment.  
Novartis  Confidential  Page 59 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
9.4 Early study termination by the sponsor  
The study can be terminated by Novartis  at any time.  
Reasons for early termination may include (but are not limited to) the following: 
• Unexpected, significant, or unacceptable safety risk to participants enrolled in the study 
• Decision based on recommendations from applicable board(s) after review of safety and 
efficacy data 
• Discontinuation of study drug development 
In taking the decision to terminate,  Novartis will always consider participant welfare and safety. 
Should early termination be necessary, participants must be seen as soon as possible and treated as a participant who discontinued from study treatment: at that time additional instructions will be provided for contacting the participant including information as to when the participant should stop taking drug, when the parti cipant should come in for a final visit(s) that the Safety 
Follow- up period must be completed if applicable and which visits to be performed. The 
investigator may be informed of additional procedures to be followed in order to ensure that adequate consider ation is given to the protection of the participant’s interests. The investigator 
or sponsor depending on local regulation will be responsible for informing IRBs/IECs of the early termination of the trial.  
10 Safety monitoring, reporting and committees 
10.1 Definition of adverse events and reporting requirements  
10.1.1 Adverse events 
An AE is any untoward medical occurrence [e.g. any unfavorable and unintended sign (including abnormal laboratory findings), symptom or disease] in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
The investigator has the responsibility for mana ging the safety of individual participant and 
identifying AEs. 
Novartis  qualified medical personnel will be readily available to advise on trial related medical 
questions or problems.  
• The occurrence of AEs must be sought by non- directive questioning of the participant at 
each visit during the study. Adverse events specified above may be detected when they are 
volunteered by the participant during or between visits or through physical examination findings, laboratory test findings, or other assessments.  
The AEs must be recorded under the signs, symptoms, or diagnosis associated with them, accompanied by the following information (as far as possible) (if the event is serious refer to  
Section  10.1.2):  
1. The severity grade:  
• mild: usually transient in nature and generally not interfering with normal activities  
Novartis  Confidential  Page 60 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
• moderate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal activities  
2. Its relationship to the investigational study drug (inclisiran/placebo) or comparator 
(ezetimibe/placebo). If the event is due to lack of efficacy or progression of underlying illness (i.e., progression of the study indication) the assessment of causality will usually be ‘Not suspected.’ The rationale for this guidance is that the symptoms of a lack of efficacy or progression of underlying illness are not caused by the trial drug, they happen in spite of its administration and/or both lack of efficacy and progression of underlying disease can only be evaluated meaningfully by an analysis of cohorts, not on a single participant. 
3. Its duration (start and end dates or ongoing) and the outcome must be reported 
4. Whether it constitutes a SAE (see  Section  10.1.2 for definition of SAE) and which 
seriousness criteria have been met.  
5. Action taken regarding investigational study drug (inclisiran/placebo) or comparator (ezetimibe/placebo). All AEs must be treated appropria tely. Treatment may include one or 
more of the following:  
• Dose not changed 
• Drug interrupted  (applicable for p.o. ezetimibe/placebo  only) 
• Permanently discontinued 
• Its outcome, which can be:  
• Not recovered / not resolved 
• Recovered / resolved  
• Recovering / resolving  
• Recovered / resolved with sequelae  
• Fatal  
• Unknown 
Conditions that were already present at the time of informed consent should be recorded in medical history of the participant.  
AEs (including lab abnormalities that constitute AEs) sho uld be described using a diagnosis 
whenever possible, rather than individual underlying signs and symptoms. 
AE monitoring should be continued for at least 30 days  following the last dose of study 
treatment.  
Once an AE is detected, it must be followed until  its resolution or until it is judged to be not 
recovered/not resolved (e.g., continuing at the end of the study), and assessment must be made 
at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the interventions required to treat it, and the outcome.  
Information about ADRs for the investigational study drug (inclisiran) can be found in the IB.  
Information about ADRs for the comparator (ezetimibe) can be found in the Package Insert.  
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least one of the following criteria:  
• they induce clinical signs or symptoms  
Novartis  Confidential  Page 61 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
• they are considered clinically significant  
• they require therapy  
Clinically significant abnormal laboratory values or test results must be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non- typical in participant 
with the underlying disease. 
As per  Section  4.7, during a Public Health emergency as declared by Local or Regional 
authorities i.e. pandemic, epidemic or natural disaster, that limits or prevents on -site study visits, 
regular phone or virtual calls can occur for safety monitoring and discussion of the participant´s health status until it is safe for the participant to visit the site again.  
10.1.2 Serious adverse events 
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria:  
• fatal 
• life-threatening  
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to the ICH E2D  Guideline 2004).  
• results in persistent or significant disability/incapacity   
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospitalization or prolongation of existing hospitalization, unless hospitalization is for:  
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition (primary hypercholesterolemia)  
• elective or pre -planned treatment for a pre-existing condition that is unrelated to the 
indication under study has not worsened since signing the informed consent 
• social reasons and respite care in the absence of any deterioration in the participant’s general condition 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospital admission 
• is medically significant, e.g. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above 
Medical and scientific judgment sh ould be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospitalization but might jeopardize the participant or mig ht 
require intervention to prevent one of the other outcomes listed above. Such events should be considered as “medically significant.” Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscras ias, or convulsions that 
Novartis  Confidential  Page 62 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
do not result in hospitalization or development of dependency or abuse (please refer to the  
ICH E2D  Guideline 2004).  
All new malignant neoplasms will be assessed  as serious under “medically significant” if other 
seriousness criteria are not met and the malignant neoplasm is not a disease progression of the 
study indication. 
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.  
All reports of intentional misuse and abuse of the product are also considered a SAE irrespective if a clinical event has occurred.  
10.1.3 SAE reporting  
To ensure participant safety, every SAE, regardless of causality, occurring afte r the participant 
has provided informed consent and until the last study visit  must be reported to Novartis safety 
immediately, without undue delay, under no circumstances later than within 24 hours of obtaining knowledge of the events (Note: If more strin gent, local regulations regarding 
reporting timelines prevail). Detailed instructions regarding the submission process and requirements are to be found in the investigator folder provided to each site. Information about all SAEs is collected and recorded o n the  Serious Adverse Event Report Form (electronic SAE 
(eSAE) form with paper backup); all applicable sections of the form must be completed in order to provide a clinically thorough report.  
The following categories of SAEs must be reported: 
1. SAEs occurring after the participant has provided informed consent until the time the 
participant is deemed a Screen Failure must be reported to  Novartis. 
2. SAEs collected between time participant signs ICF until the participant has completed the End of Study Vis it 
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
immediately, without undue delay, but under no circumstances later than within 24 hours of the investigator receiving the follow -up information (Note: If more stringent, local regulations 
regarding reporting timelines prevail). An SAE occurring at a different time interval or otherwise considered completely unrelated to a  previously reported one must be reported 
separately as a new event.  
If the SAE is not previously documented in the IB or Package Insert (new occurrence) and is thought to be related to the study treatment, a Chief Medical Office and Patient Safety (CMO&PS ) Department associate may urgently require further information from the 
investigator for health authority reporting.  Novartis  may need to issue an IN to inform all 
investigators involved in any study with the same study treatment that this SAE has been reported. 
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to the competent authorities and relevant ethics committees in accordance with EU Guidance 2011/C 172/01, EU Clinical Trial Regulation 536/2014 (if applicable) or as per national regulatory requirements in participating countries. 
Novartis  Confidential  Page 63 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Any SAEs experienced after the last study visit  should only be reported to Novartis Safety if 
the investigator suspects a causal relationship to study treatment, unless otherwise specified by 
local law/regulations.  
10.1.4 Pregnancy reporting  
If a female trial participant becomes pregnant, the study treatment should be stopped, and the pregnancy consent form should be presented to the trial participant. The participant must be given adequate time  to read, review and sign the pregnancy consent form. This consent form is 
necessary to allow the investigator to collect and report information regarding the pregnancy. To ensure participant safety, each pregnancy occurring after signing the informed consent must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects , congenital abnormalities, or maternal 
and/or newborn complications. 
Pregnancy should be recorded and reported by the investigator to the Novartis  CMO&PS. 
Pregnancy follow -up should be recorded on the same form and should include an assessment 
of the poss ible relationship to the study treatment any pregnancy outcome. Any SAE 
experienced during pregnancy must be reported. After consent is provided, the pregnancy reporting will occur up to one year after the estimated 
date of delivery.  
10.1.5 Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration, or monitoring of a medicine while under the control of a healthcare professional, participant or consumer (European Medicines Agency (EMA) definition).  
Misuse refers to situations where the medicinal product is intentionally and inappropriately used not in accordance with the protocol. 
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied by harmful physical or psychological effects. 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate eCRF irrespective of whether or not associated with an AE/ SAE, and reported 
to Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the safety database irrespective of it being associated with an AE/SAE within 24 hours of investigator’s awareness.  
Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse 
Treatment error type  Document in Dosing 
eCRF (Yes/No)  Document in AE eCRF  Complete SAE form  
Unintentional study 
treatm ent error  Yes Only if associated with an 
AE Only if associated with an 
SAE 
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE  
Novartis  Confidential  Page 64 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.  
10.2 Additional Safety Monitoring  
10.2.1 Liver safety monitoring 
To ensure participant safety and enhance reliability in determining the hepatotoxic potential of an investigational drug, a standardized process for identification, monitoring and evaluation of liver eve nts has to be followed. 
Please refer to  Table  16-1 in  Section  16.2 for complete definitions of liver laboratory triggers.  
Once a participant is exposed to study treatment, every liver event defined in  Table  16-1 should 
be followed up by the investigator or designated personnel at the trial site, as summarized bel ow. 
Additional details on actions required in case of liver events are outlined in Table  16-2 and 
Table  16-3 ( Section  16.2 ). Repeat liver chemistry tests (i.e., ALT, AST, TBL, albumin, CK, 
GLDH, PT/INR, ALP and GGT) to confirm elevation. These liver chemistry repeats will be performed using the central laboratory. If results will not be available from the central laboratory, then the repeats can also be performed at a local laboratory to monitor the safety of the participant. If a liver event is subsequently reported, any local liver chemistry tests previously conducted that are associated with this event should have results recorded on the appropriate eCRF.  
• If the initial elevation is confirmed, close observation of the participant will be initiated, including consideration of treatment interruption if d eemed appropriate. 
• Discontinuation of the investigational drug (refer to the Discontinuation of study treatment section), if appropriate 
• Hospitalization of the participant if appropriate  
• Causality assessment of the liver event  
• Thorough follow-up of the liver event should include (based on investigator’s discretion): serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease 
All follow -up information and procedures performed must be recorded as appropriate in the 
eCRF.  
10.2.2 Renal safety monitoring 
Once a participant is exposed to study treatment, either of the following two categories of abnormal renal laboratory alert values should be assessed during the study period: 
• Serum creatinine increase ≥ 25% compared to baseline and value above ULN during 
normal hydration status 
• Any one of the following:  
• Urine protein- creatinine ratio (PCR) ≥ 1g/g or ≥ 100 mg/mmol, OR 
• New onset dipstick proteinuria ≥ 3+, OR  
Novartis  Confidential  Page 65 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
• New onset dipstick hematuria ≥ 3+ (after excluding menstruation, urinary tract 
infection, extreme exercise, or trauma)  
Abnormal renal event findings must be confirmed with repeat test done at central lab  after  
≥ 24 hours but ≤ 5 days after first assessment.  
Once a participant is exposed to study treatment, renal laboratory alerts or renal safety events should be monitored and followed up by the investigator or designated trial staff. 
10.3 Committees  
There are no committees for this trial.  
11 Data Collection and Database management  
11.1 Data collection  
Designated investigator staff will enter the data required by the protocol into the eCRF. The eCRFs have been built using fully validated secure web- enabled software tha t conforms to  
21 Code of Federal Regulations (CFR) Part 11 requirements, Investigator site staff will not be given access to the EDC system until they have been trained. Automatic validation programs check for data discrepancies in the eCRFs, allow modifi cation and/or verification of the entered 
data by the investigator staff.  
The investigator/designee is responsible for assuring that the data entered into eCRF is complete, accurate, and that entry and updates are performed in a timely manner. The Investigator must certify that the data entered are complete and accurate.  
After final database lock, the investigator will receive copies of the participant data for archiving at the investigational site.  
All data should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification.  
11.2 Database management and quality control  
Novartis  personnel (or designated contract research organization (CRO)) will review the data 
entered by investigational staff for completeness and  accuracy. Electronic data queries stating 
the nature of the problem and requesting clarification will be created for discrepancies and missing values and sent to the investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data.  
Concomitant treatments and prior medications entered into the database will be coded using the World Health Organization (WHO) Drug Reference List, which employs the Anatomical 
Therapeutic Chemical (ACT) classification system. Medical history/current medical conditions 
and AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
Dates of screenings, randomizations, screen failures and study completion, as well as 
randomization codes and data about all study treatment (s) dispensed to the participant and all 
Novartis  Confidential  Page 66 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
dosage changes will be tracked using an IRT. The system will be supplied by a vendor, who 
will also manage the database. The data will be sent electronically to  Novartis  (or a designated 
CRO) at specific timelines.  
Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The code break functionality will remain available until study shut down or upon request of  Novartis.  
Once all the necessary actions have been completed and the database has been declared to be complete and accurate, it will be locked and the treatment codes will be unblinded and made available for data analysis/moved to restricted  area to be accessed by independent programmer 
and statistician. Any changes to the database after that time can only be made after written agreement by  Novartis  development management. 
11.3 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and data capture requirements (i.e., eCRFs) with the investigators and their staff. During the study,  Novartis employs several methods of ensuring 
protocol and GCP compliance  and the quality/integrity of the sites’ data. The field monitor will 
visit the site to check the completeness of participant records, the accuracy of data capture / data entry, the adherence to the protocol and to GCP, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits. Continuous remote monitoring of each site’s data may be performed by a centralized Novartis/CRA organization. Additionally, a central analytics organization may analyze data and identify risks and trends for site operational parameters, and provide reports to Novartis  clinical teams to 
assist with trial oversight.  
The investigator must maintain source documents for each participant in the study, consisting 
of case and visit notes (hospital or clinic medical records) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on eCRFs must be traceable to these source documents in the participant's file. The investigator must also keep the original ICF signed by the participant (a signed copy is given to the participant). 
The inves tigator must give the monitor access to all relevant source documents to confirm their 
consistency with the data capture and/or data entry. Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the eCRFs are performed according to the study- specific monitoring plan. No information in source documents about the identity of the 
participants will be disclosed.  
12 Data analysis and statistical methods 
12.1 Analysis sets  
The following analysis sets will be used for statistical analyses:  
Novartis  Confidential  Page 67 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
The screened set (SCR) consists of all participants who signe d the informed consent. The SCR 
includes only unique screened participants, i.e., in the case of re -screened participants only the 
chronologically last screening data is counted. 
The Randomized Analysis Set (RAS) consists of all participants who received a randomization 
number, regardless of receiving trial medication.  
The Full Analysis Set (FAS) comprises all randomized participants with the exception of those participants who have not been qualified for randomization and have not received study drug, but have been inadvertently randomized into the study. Following the intent -to-treat (ITT) 
principle, participants will be analyzed according to the treatment they have been assigned to at randomization. Efficacy variables will be analyzed based on the FAS.  
The Safety Analysis Set (SAF) includes all participants who received at least one dose of study 
drug. Participants will be analyzed according to the study treatment actually received. The SAF will be used for the analyses of safety variables.  
Note: The last part of the definition of the FAS is what is often referred to as misrandomized participants; i.e. participants for whom IRT calls were made by the site either prematurely or inappropriately prior to confirmation of the participant’s final randomization eligibility and double- blind medication was not administered to the participant. These participants would 
subsequently not continue to take part in the study or be followed -up. Misrandomized 
participants will not be included in the FAS, but they will be included in the RAS. Further exclusions from the FAS may only be justified in exceptional circumstances (e.g., serious GCP violations).  
12.2 Participant demographics and other baseline characteristics  
The number of participants screened, randomized and included in the FAS will be presented by treatment group and overall, for the SCR. In addition, the reasons for discontinuation prior to randomization will be provided for the SCR as well. The number and percentage of participants in the RAS who completed the study, who discontinued the study and the reason for discontinuation from study will be presented for each treatment group and all participants. The frequency (%) of participants with protocol deviations as well as the criteria leading to data exclusion from analysis will be presented in separate tables for the RAS. Finally, the number of enrolled and randomized participants by region will be presented descriptively for the RAS. 
Baseline value is defined as the last non -missing assessment prior to the first dose of study drug 
unless specified otherwise.  
Demographic and other baseline data will be summarized descriptively by treatment group for 
the FAS. Categorical data will be presented as frequencies and percentages. Continuous variables will be summarized using n,  mean, standard deviation, median, Q1 (25
th percentile), 
Q3 (75th percentile), minimum, and maximum.  
Relevant medical histories and current medical conditions at baseline will be summarized by system organ class and preferred term, separately by treatment group. 
Other study specific medical history will also be summarized  appropriately. 
Novartis  Confidential  Page 68 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
12.3 Treatments  
The SAF will be used for the analyses in this section. Categorical data will be summarized as 
frequencies and percentages. For continuous data, number of non- missing observations, mean, 
standard deviation, median, 25th and 75th percentiles, minimum, and maximum will be presented.  
Study drug 
The duration of the double -blind treatment will be computed as the time from the first 
administration of study drug to the fir st of the following events to occur:  
• the last administration plus 180 days for inclisiran or plus 1 day for ezetimibe and placebo, 
• the participant’s death, or 
• the participant’s study completion visit or last contact.  
This algorithm reflects the planned treatment schedule and the exposure attributable period of 
the study drug. The duration of the double -blind treatment period will be summarized for the 
SAF by treatment group descriptively. The overall participant years of treatment will be compute d as the sum of participant years of double -blind treatment for all participants.  
The number of study doses administered will also be summarized by treatment group. 
Prior and concomitant therapies 
Prior or concomitant medications will be summarized for the  SAF in separate tabulations based 
on the coding dictionary used. Medications will be presented in alphabetical order, by preferred 
terms and grouped by anatomical main group, according to the ATC classification system. Tables will show the overall number and percent of participants receiving at least one drug of a particular preferred term and at least one drug in a particular anatomical main group.  
Prior medications and significant non -drug therapies are defined as any medications and 
significant non -drug therapies taken prior to the randomization visit. Concomitant medications 
and significant non- drug therapies are defined as those used during the double -blind period. 
Concomitant medications that were prohibited as per protocol and given during the conduc t of 
the study as well as significant non -drug therapies will be summarized.  
12.4 Analysis supporting primary objectives  
The primary aim of the study is to demonstrate the superiority of inclisiran to either placebo or ezetimibe in reducing LDL -C. 
The FAS will be used for the primary efficacy analysis.  
12.4.1 Definition of primary endpoint(s)  
The primary endpoint of the study is the percentage change from baseline to Day 150 in  
LDL -C. 
Novartis  Confidential  Page 69 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
12.4.2 Statistical model, hypothesis, and method of analysis 
The primary objectives are to demonstrate the superiority of inclisiran as monotherapy 
compared to the use of placebo or ezetimibe separately, in reducing LDL -C as measured by 
percentage change from baseline to Day 150. To this end, the Monotherapy Estimand assess es 
the treatment effect of inclisiran alone in the absence of confounding factors such as additional LLT.  
As described  in Section  2.1, in addition to the primary  Monotherapy Estimand, the Treatm ent-
policy Estimand was  added for regulatory purposes . Both estimands will be considered in 
parallel as primary analysis.  
The primary statistical hypotheses to be tested are:  
• H
IP0: μi - μp ≥ 0 vs. H IPa: μi - μp < 0 
• HIE0: μi - μe ≥ 0 vs. H IEa: μi - μe < 0 
where μ i, μp and μ e are the mean percentage changes in LDL -C from baseline to Day 150 in the 
inclisiran group, placebo group, and ezetimibe group respectively. The study can be claimed a success if at least one of the above two individual hypotheses is rej ected.  
The primary efficacy endpoint will be analyzed using an Analysis of Covariance (ANCOVA) model with treatment, stratification factor, and baseline value as fixed effects. Due to probable heterogeneity of variances between treatment groups, an ANCOVA model that assumes unequal variances between treatment groups will be used. The two primary endpoint hypotheses will be tested using an equally weighted Dunnett test ( Dunnett 1955 ). 
The multiple comparison procedure (MCP) will be used in statistical hypothesis testing  for 
primary and secondary endpoints  to control the overall type I error rate at 0.025 (one -sided test).  
For each of the secondary efficacy endpoints, the Treatment -policy Es timand and the 
Monotherapy Estimand will be defined in a similar way as for the primary endpoint, and t he 
MCP will be applied to Monotherapy Estimands and Treatment -policy Estimands separately, 
to control the overall type I error rate within each set of es timands.  Since the Treatment -policy 
Estimands are intended for regulatory purposes, while  the Monotherapy Estimands are intended 
for all other purposes, no multiplicity adjustment will be made across those two sets of 
estimands. The testing procedure to be  followed is graphically presented in  Figure 12-1, and 
outlined in the following steps: 
• First, a weighted Dunnett test with equal weights assigned to each of the two individual 
primary hypothe ses (H
IP0 and H IE0) is performed. This test will exploit the correlation of 
the primary endpoint between the two comparisons, with the test statistics derived from the ANCOVA model described as above.  
• If one primary hypothesis is rejected, a fraction of its significance level will be passed to the other primary hypothesis while the remaining alpha will be propagated to the family of secondary hypotheses under the same treatment comparison, according to the pre-specified weights as indicated in  the graph. The choice of weights for passing alpha to the 
other primary hypothesis (0.4 and 0.6 respectively) reflects the importance of demonstrating efficacy in the comparison between inclisiran and placebo. 
• Within a family of secondary hypotheses (H
IPk or H IEk), the hierarchical testing procedure 
will be used. Refer to  Section  12.5.1 for details.  
Novartis  Confidential  Page 70 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
• If one secondary hypothesis in the comparison between inclisiran and placebo H IPk is 
rejected, a fraction of its significance level will be passed to the next hierarchy of 
secondary hypotheses under the same treatment comparison, while the remaining alpha will be propagated to the primary hypothesis comparing inclisiran and ezetimibe. If there is no next hierarchy of secondary hypotheses, then the whole alpha will be propagated to the primary hypothesis comparing inclisiran and ezetimibe. Vice  versa for the alpha 
passing from H
IEk. 
The nodes H IP and H IPk represent the null hypotheses related to the primary and secondary 
endpoints compared between inclisiran and placebo, while the nodes H IE and H IEk represent the 
null hypotheses related to the primary and secondary endpoints compared between inclisiran and ezetimibe. The correlations between endpoints and between the two comparisons for each endpoint will also be considered. 
The least squares means for the difference between inclisiran and two comparators and 
corresponding unadjusted two- sided confidence intervals (CI) will be provided s eparately. The 
raw p -value for testing the individual hypothesis will also be provided. The superiority of 
inclisiran to a comparator can be claimed when the corresponding individual null hypothesis is rejected or the raw p -value is statistically significant at corresponding alpha level of current 
stage.  
12.4.3 Handling of intercurrent events of primary estimands 
The Monotherapy Estimand will account for different intercurrent events as explained in the 
following:  
• Discontinuation of study treatment: Discontinuation of study treatments will be treated in a hypothetical scenario of what would happen if the participants had not discontinued study treatments (hypothetical strategy).  
• Death:  Participants who die will be treated in a hypothetical scenario of what would 
happen if participants had not died (hypothetical strategy).  
• Use of lipid -lowering therapy:  Use of LLT will be treated in a hypothetical scenario of 
what would happen if other LLT were not available (hypothetical strategy).  
The efficacy endpoints after the intercurrent events will be multiply imputed under the missing -
at-random assumption.  
The Treatment -policy Estimand will account for intercurrent events as follows:  
• Discontinuation of study treatment: Retrieved dropout (RDO) data collected after discontinuation from study treatment s will be used for the analysis (treatment- policy  
strategy).  Missing data after discontinuation from study treatments will be multiply 
imputed based on RDO data, and when there are no sufficient RDO data, a placebo -based 
Pattern -Mixture Model (PMM) will be used for multiple imputation.  
• Death:  A composite variable strategy will be utilized to handle the intercurrent event of 
death, and efficacy parameter measurements after death will be imputed using the subject’s baseline values.  
Novartis  Confidential  Page 71 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
• Use of lipid -lowering therapy:  The data collected after use of other LLTs will be used  
for analyses (treatment -policy strategy). Missing data will be  multiply  imputed using a 
placebo -based PMM.  
The primary analysis will be conducted on each multiply imputed dataset, and the treatment 
effects estimated from each of those imputed datasets wil l be combined using Rubin’s method 
(Rubin 1987).  
The details will be in the statistical analysis plan (SAP).  
12.4.4 Handling of missing values not related to intercurrent event  
In the Monotherapy Estimand, missing values not related to intercurrent events will be multiply imputed under the missing- at-random assumption. In the Treatment -policy Estimand, missing 
values not related to intercurrent events will be multiply imputed using a placebo -based PMM. 
The primary analysis will be conducted on each  multiply  imputed dataset, and the treatment 
effects estimated from each of those imputed datasets will be combined using Rubin’s method (Rubin 1987). D etails will be given in the SAP.  
12.4.5 Sensitivity analyses  
Sensitivity analy ses such as tipping point analyses will be conducted to assess the robustness of 
the inferences to various assumptions about the missing data , and details will be provided in the  
SAP.  
12.4.6 Supplementary analysis 
If necessary, supplementary analyses will be conducted and described in the SAP . 
Subgroup analyses  
Subgroup analyses to assess the homogeneity of the treatment effect across demographic and baseline characteristics may be performed. All subgroup analyses will be defined in the SAP prior to database lock. 
12.5 Analysis supporting secondary obj ectives 
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s)  
There are seven secondary efficacy endpoints defined, and fourteen secondary hypotheses to be tested for these seven secondary endpoints in the comparison between inclisiran and each comparator (placebo or ezetimibe) respectively:  
1. Percentage change in PCSK9 from baseline to Day 150 
2. Absolute change in LDL-C from baseline to Day 150 
3. Percentage change in non- HDL -C from baseline to Day 150 
4. Percentage change in TC/HDL -C ratio from baseline to Day 150 
5. Percentage change in Apo B from baseline to Day 150 
6. Percentage change in Apo B/Apo A-1 ratio from baseline to Day 150 
7. Percentage change in Lp (a) from baseline to Day 150 
Novartis  Confidential  Page 72 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
For each of the secondary efficacy endpoints, the Treatment -policy Estimand and the 
Monotherapy Estimand will be defined in a similar way as for the primary endpoint. All 
secondary efficacy endpoints will be analyzed on FAS using the same ANCOVA model as for 
the primary efficacy endpoint as described in  Section 12.4.2. Lipoprotein (a) will be log-
transformed before modeling. The model will include treatment, stratification factor, and baseline value as fixed effects, and assume unequal variances between treatment groups. The least squares means for the difference between inclisiran and two comparators and corresponding unadjusted two-sided CIs will be provided separately. 
As stated in  Section  12.4.2, the two families of secondary hypotheses H
IPk and H IEk (k = 1, 2, ..., 
7, following the order of the seven secondary endpoints as above) are included in the multiple 
testing procedure as presented in Figure 12-1. The hierarchical testing procedure will be used 
to test the seven secondary hypotheses within each family of the secondary endpoints (H IPk or 
HIEk). If one secondary hypothesis in the comparison between inclisiran and placebo H IPk is 
rejec ted, a fraction of its significance level will be passed to the next hierarchy of secondary 
hypotheses under the same treatment comparison, while the remaining alpha will be propagated to the primary hypothesis comparing inclisiran and ezetimibe, according  to the pre -specified 
weights as indicated in the graph. If there is no next hierarchy of secondary hypotheses, then the whole alpha will be propagated to the primary hypothesis comparing inclisiran and ezetimibe. Vice versa for the alpha passing from H
IEk. 
Novartis  Confidential  Page 73 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Figure 12-1 Testing procedure for primary and secondary endpoints 
 
The intercurrent events and missing values  will be handled following the same approach as 
described fo r the primary endpoint s. Details of the analyses for secondary efficacy endpoints 
and sensitivity analyses if necessary will be specified in the SAP.  
12.5.2 Safety endpoints 
For all safety analyses, the SAF will be used. All tables and listings will be presented by 
treatment group . 
Safety data will be summarized by treatment groups. Baseline data will be summarized where appropriate (for change from baseline summaries).  
Novartis  Confidential  Page 75 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
12.8 Sample size calculation  
12.8.1 Primary endpoint(s)  
The sample size calculation was based on a two sample t -test for the hypothesis that inclisiran 
is superior to either p lacebo or ezetimibe in terms of mean percentage change from baseline to 
Day 150 in LDL -C, at a one -sided significance level of 0.0125 (assuming a more conservative 
Bonferroni alpha split between the two primary hypotheses). 
The sample size of 280 completer s in total (with randomization ratio of 2:1:1 to inclisiran, 
placebo, and ezetimibe arms) will provide at least 99% power to detect a 40% difference 
between inclisiran and placebo or a 20% difference between inclisiran and ezetimibe at significance level o f 0.0125 (one -sided test) assuming 30% for the standard deviation. Adjusted 
for 6% potential dropouts, approximately 300 participants in total will be randomized with a 2:1:1 ratio, i.e., 150 participants in the inclisiran arm, and 75 participants in both the placebo and ezetimibe arm.  
12.8.2 Secondary endpoint(s)  
Statistical power will not be assessed for secondary endpoints.  
13 Ethical considerations and administrative procedures 
13.1 Regulatory and ethical compliance  
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) international ethical guidelines  
• Applicable IC H Good Clinical Practice (GCP) guidelines  
• Applicable laws and regulations 
This clinical study was designed and shall be implemented, executed and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicab le 
local regulations (including European Directive 2001/20/EC, US CFR 21 or European Clinical Trial Regulation 536/2014, US  CFR 21), and with the ethical principles laid down in the 
Declaration of Helsinki.  
13.2 Responsibilities of the investigator and IRB/IEC  
The protocol, protocol amendments, ICF, IB, and other relevant documents  
(e.g. advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and approved by the IRB/IEC before the study is initiated. 
The Investigator will be responsible  for the following: 
Signing a protocol signature page confirming his/her agreement to conduct the study in 
accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to Novartis monitors, auditors, 
Novartis  Confidential  Page 76 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Novartis Quality Assurance representatives, designated agents of Novartis, IRBs/IECs, and 
regulatory authorities as required. 
Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently  in accordance with the requirements, policies, and procedures established by the 
IRB/IEC.  
Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures. 
Providing oversight of the conduct of the study at the site and adherence to requirements of  
21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations. 
Inform Novartis immediately if an inspection of the clinical site is requested by a regulatory 
authority. 
13.3 Publication of study protocol and results  
The protocol will be registered in a publicly accessible database such as clinicaltrials.gov and as required in European Union Drug Regulating Authorities Clinical Trials Databa se (EudraCT) 
or EMA's Clinical Trials Information System (CTIS) public website. In addition, after study completion (defined as last patient last visit) and finalization of the study report the results of this trial will be submitted for publication and posted in a publicly accessible database of clinical trial results, such as the Novartis clinical trial results website and all required Health Authority websites (e.g. Clinicaltrials.gov, EudraCT or CTIS public website etc.) .  
For details on the  Novartis publication policy including authorship criteria, please refer to the  
Novartis  publication policy training materials that were provided to you at the trial investigator 
meetings.  
Any data analysis carried out independently by the Investigator should be submitted to Novartis before publication or presentation. 
Summary results of primary and secondary endpoints will be disclosed based upon the global 
Last Participant Last Visit (LPLV) date, since multinational studies are locked and reported based upon the gl obal LPLV.  
13.4 Quality Control and Quality Assurance  
Novartis  maintains a robust Quality Management System (QMS) that includes all activities 
involved in quality assurance and quality control, to ensure compliance with written Standard Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines.  
Audits of investigator sites, vendors, and Novartis systems are performed by auditors, independent from those involved in conducting, monitoring or performing quality control of the clinic al trial. The clinical audit process uses a knowledge/risk based approach.  
Audits are conducted to assess GCP compliance with global and local regulatory requirements, protocols and internal SOPs, and are performed according to written Novartis processes. 
Novartis  Confidential  Page 77 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
13.5 Participant Engagement  
The following participant engagement initiatives are included in this study and will be provided, 
as available, for distribution to study participants at the timepoints indicated. If compliance is impacted by cultural norms or local laws and regulations, sites may discuss modifications to 
these requirements with Novartis.  
• Thank You letter 
• Plain language trial summary - after CSR publication  
• Individual study results - after CSR publication  
• Trial Feedback Questionnaires (TFQ) - start an d end of trial 
13.6 Data Protection  
Participants will be assigned a unique identifier by Novartis. Any participant records or datasets that are transferred to Novartis will contain the identifier only; participant names or any information which would make the participant identifiable will not be transferred.  
The participant must be informed that his/her personal study -related data will be used by 
Novartis in accordance with local data protection law. The level of disclosure must also be explained to the participant who will be required to give consent for their data to be used as described in the informed consent. 
The participant must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by Novartis, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
Novartis has appropriate processes and policies in place to handle personal data breaches according to applicable privacy laws.  
14 Protocol adherence 
This protocol defines the study objectives, the study procedures and the data to be collected on study participants. Additional assessments required to ensure safety of participants should be administered as deemed necessary on a case by case basis. Under no circumst ances including 
incidental collection is an investigator allowed to collect additional data or conduct any additional procedures for any purpose involving any investigational drugs under the protocol, other than the purpose of the study. If despite this in terdiction prohibition, data, information, 
observation would be incidentally collected, the investigator shall immediately disclose it to Novartis and not use it for any purpose other than the study, except for the appropriate monitoring on study participants. 
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study this must be considered a protocol amendment, and unless such an amendment is agreed upon by Novartis and approved by the IRB/IEC and Health Authorities, where required, it cannot be implemented.  
Novartis  Confidential  Page 78 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
14.1 Protocol amendments  
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementation.  
Only amendments that are required for participant safety may be implemented immediately provided the health authorities are subsequently notified by protocol amendment and the reviewing IRB/IEC is notified.  
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any participant included in this study, even if this action represents a deviation from the protocol. In such cases, Novartis should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.  
Novartis  Confidential  Page 79 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
15 References 
References are available upon request  
Arnett DK, Blumenthal RS, Albert MA, et al (2019) 2019 ACC/AHA Guideline on the 
Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines . 
Circulation; 140(11):e596 -e646. 
Assmann G, Benecke H, Neiss A, et al (2006) Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E- Registry (Efficacy Calculation and Measurement of Cardiovascular 
and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil; 13(5):776-83. 
Banach M, Stulc T, Dent R, et al (2016) Statin non- adherence and residual cardiovascular 
risk: There is need for substantial impr ovement. Int J Cardiol; 225:184-96. 
Brown MS, Goldstein JL (2006) Biomedicine. Lowering LDL --not only how low, but how 
long? Science; 311(5768):1721-3. 
Dunnett, CW (1955) A multiple comparison procedure for comparing several treatments with 
a control. Journal of the American Statistical Association, 50(272):1096-121. 
Fitzgerald K, White S, Borodovsky A, et al (2017) A Highly Durable RNAi Therapeutic 
Inhibitor of PCSK9. N Engl J Med; 376(1):41-51. 
Fox KM, Tai MH, Kostev K, et al (2018) Treatment patterns and low-density lipoprotein 
cholesterol (LDL -C) goal attainment among patients receiving high - or moderate -intensity 
statins. Clin Res Cardiol; 107:380-8. 
Grundy SM, Stone NJ, Bailey AL, et al (2019) 2018 
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol; 73(24):e285-e350. 
Horton JD, Cohen JC, Hobbs HH (2007) Molecular bi ology of PCSK9: its role in LDL 
metabolism. Trends Biochem Sci; 32(2):71 -7. 
ICH E2D Guideline (2004) ICH E2D Post- approval safety data management (Internet) 
Available from: <ema.europa.eu/en/ich-e2d-post-approval- safety -data-management> 
(Accessed 04 -May-2022).  
ICH E6 Guideline (2017) ICH E6 (R2) Good clinical practice (Internet) Available from: 
<ema.europa.eu/en/ich -e6-r2-good- clinical -practice> (Accessed on: 04 -May-2022). 
Lakoski SG, Lagace TA, Cohen JC, et al (2009) Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab; 94(7):2537-43. 
Mach F, Baigent C, Catapano AL, et al (2020) 2019 ESC/EAS Guidelines for the 
management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J; 41(1):111- 88. 
Novartis  Confidential  Page 80 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Mousavi SA, Berge KE, Leren TP (2009) The unique role of proprotein convertase 
subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med; 266:507-19. 
Navarese EP, Kolodziejczak M, Schulze V, et al (2015) Effects of Proprotein Convertase 
Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med; 163(1):40-51. 
Raal FJ, Kallend D, Ray KK, et al (2020) Inclisiran for the Treatment of Heterozygous 
Familial Hypercholesterolemia. N Engl J Med; 382(16):1520-30. 
Ray KK, Wright RS, Kallend D, et al (2020) Two Phase 3 Trials of Inclisiran in Patients with 
Elevated LDL Cholesterol. N Engl J Med; 382(16):1507-19. 
Rubin, DB (1987) Underlying Bayesian Therapy. In: Multiple Imputation for Nonresponse in 
Surveys. John Wiley & Sons Inc, p. 75-112. 
Sabatine MS, Giugliano RP, Keech AC, et al (2017) Evolocumab and Clinical Outcomes in 
Patients with Cardiovascular Disease. N Engl J Med; 376(18):1713-22. 
Schwartz GG, Steg PG, Szarek M, et al (2018) Alirocumab and Cardiovascular Outcomes 
after Acute Coronary Syndrome. N Engl J Med; 379(22):2097107. 
WHO (2021) Cardiovascular diseases (CVDs) (Internet) Available from: <who.int/news -
room/fact- sheets/detail/cardiovascular- diseases -(cvds)> (Accessed 22 -Apr-2022). 
Wright RS, Ray KK,  Raal FJ, et al (2021) Pooled Patient- Level Analysis of Inclisiran Trials 
in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol; 
77(9):1182-93. 
Zhang XL, Zhu QQ, Zhu L, et al (2015) Safety and efficacy of anti-PCSK9 antibodie s: a 
meta -analysis of 25 randomized, controlled trials. BMC Med; 13:123. 
Novartis  Confidential  Page 81 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
16 Appendices  
16.1 Appendix 1: Clinically notable laboratory values and vital signs  
The central laboratory will flag laboratory values falling outside of the normal ranges on the 
central labo ratory reports. Investigators are responsible for reviewing these abnormal values for 
clinical significance, signing the laboratory reports to indicate their review, and reporting values considered clinically significant in the appropriate eCRF.  
Any clinically significant abnormal laboratory value should be evaluated and followed- up by 
the investigator until normal or a cause for the abnormality is determined.  
See Section  16.2 for specific liver event and laboratory test trigger definitions and follow -up 
requirements.  
Novartis  Confidential  Page 82 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
16.2 Appendix 2: Liver event and laboratory trigger definitions & 
follow -up requirements  
Table 16-1 Liver laboratory trigger definitions 
Liver laboratory triggers  Definition/ threshold  
If ALT, AST and TBL normal at baseline:  ● ALT or AST > 3.0 × ULN  
● TBL > 1.5 × ULN  
● ALP > 2.0 × ULN (in the absence of known bone pathology)  
If ALT, AST, or TBL abnormal at baseline:  ● ALT or AST > 2 x baseline or > 300 U/L, whichever occurs first  
● TBL > 2 x baseline and > 2.0 x ULN  
Table 16-2 Follow -up requirements for liver laboratory triggers - ALT, AST, TBL  
ALT or AST  TBL Liver Symptoms  Action  
ALT or AST increase without TBL increase:  
If normal at baseline:  
ALT or AST > 3.0 x ULN  Normal  
For participants with Gilbert’s syndrome: No 
change in baseline TBL  None  • No change to study 
treatment  
• Measure ALT, AST, ALP, 
GGT, TBL, PT/INR, 
albumin, CK, and GLDH 
in 48- 72 hours.  
• Follow -up for symptoms.  If elevated at baseline:  
ALT or AST > 2 x baseline  
If normal at baseline:  
ALT or AST > 5.0 x ULN 
for more than two weeks  Normal  
For participants with Gilbert’s syndrome: No 
change in baseline TBL  None  • Interrupt study 
treatment  
• Measure ALT, AST, ALP, GGT, TBL, PT/INR, 
albumin, CK, and GLDH 
in 48- 72 hours.  
• Follow -up for symptoms.  
• Initiate close monitoring and workup for 
competing etiologies.  
• Study treatment  can be 
restarted only if another etiology is identiﬁed and 
liver enzymes return to 
baseline.  
• If no cause can be 
identified to explain the 
elevation in liver 
enzymes, then study 
treatment must be 
discontinued.  If elevated at baseline:  
ALT or AST > 3 x baseline 
for more than two weeks  
If normal at baseline:  
ALT or AST > 8.0 x ULN  Normal  None  
ALT or AST increase with TBL increase:  
If normal at baseline:  
ALT or AST > 3.0 x ULN  TBL > 2.0 x ULN (or 
INR > 1.5)  
For participants with 
Gilbert’s syndrome: 
Doubling of direct 
bilirubin  None  
If elevated at baseline:  
ALT or AST > 2 x baseline  
If normal at baseline:  
ALT or AST > 3.0 x ULN  Normal or elevated  Severe fatigue, 
nausea, vomiting, right upper quadrant 
pain If elevated at baseline:  
ALT or AST > 2 x baseline  
Novartis  Confidential  Page 83 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
Table 16-3 Follow -up requirements for liver laboratory triggers - Isolated 
Hyperbilirubinemia or elevated ALP  
Criteria  Actions required  Follow -up monitoring  
Elevated TBL (isolated)  
> 1.5 – 3.0 x ULN  • Maintain treatment  
• Repeat LFTs within 48-72 hours  Monitor LFTs weekly until resolution 
to ≤ Grade 1 (≤ 1.5 x ULN) or to 
baseline  
> 3.0 - 10.0 x ULN  
(in the absence of known 
Gilbert syndrome)  • Interrupt treatment  
• Repeat LFT within 48-72 hours  
• Hospitalize if clinically 
appropriate  
• Establish causality  
• Record the AE and contributing factors (e.g. concomitant 
medications, medical history, 
lab) in the appropriate eCRF  Monitor LFTs weekly until resolution 
to ≤ Grade 1 (≤ 1.5 x ULN) or to 
baseline (ALT, AST, TBL, albumin, CK, GLDH, PT/INR, ALP and GGT)  
Test for hemolysis (e.g. 
reticulocytes, haptoglobin, 
unconjugated [indirect] bilirubin)  
> 10.0 x ULN  • Discontinue the study treatment 
immediately  
• Hospitalize the participant  
• Establish causality  
• Record the AE and contributing factors (e.g. concomitant 
medications, medical history, 
lab) in the appropriate eCRF  ALT, AST , TBL, albumin, CK, 
GLDH, PT/INR, ALP and GGT until resolution (frequency at investigator discretion)  
Any AE potentially indicative of a liver toxicity  • Consider study treatment 
interruption or discontinuation  
• Hospitalization if clinically appropriate  
• Establish causality  
• Record the AE and contributing factors (e.g., concomitant medications, medical  history, 
lab) in the appropriate eCRF  Investigator discretion  
Elevated ALP (isolated)  
> 2.0 x ULN  • Maintain treatment  
• Repeat LFTs within 48 -72 hours  Investigator discretion  
Monitor LFT within 1 to 4 weeks or 
at next  visit 
Based on investigator’s discretion investigation(s) for contributing factors for the liver event 
can include: Serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease. 
Novartis  Confidential  Page 84 of 84 
Amended Protocol Version 01 (Clean )  Protocol No. CKJX839D12304  
 
16.3 Appendix 3: Specific Renal Alert Criteria and Actions and Event 
Follow -up 
Refer to Section  10.2.2. 